Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:sirolimus
go back to main search page
Accession:CHEBI:9168 term browser browse the term
Definition:A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.
Synonyms:exact_synonym: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
 related_synonym: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone;   Antibiotic AY 22989;   Formula=C51H79NO13;   InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1;   InChIKey=QFJCIRLUMZQUOT-HPLJOQBZSA-N;   Rapamune;   SMILES=[H][C@]1(CC[C@@H](O)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC;   rapamycin;   sirolimusum
 alt_id: CHEBI:45276;   CHEBI:67812
 xref: CAS:53123-88-9;   DrugBank:DB00877;   Drug_Central:2446;   HMDB:HMDB0015015;   KEGG:C07909;   KEGG:D00753;   KNApSAcK:C00018055;   LIPID_MAPS_instance:LMPK06000003
 xref_mesh: MESH:D020123
 xref: PDBeChem:RAP;   PMID:22960739;   PMID:22981852;   PMID:22984623;   Reaxys:5848501;   Wikipedia:Rapamycin


show annotations for term's descendants           Sort by:
 
sirolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2M alpha-2-macroglobulin increases expression ISO Sirolimus results in increased expression of A2M mRNA CTD PMID:21865292 NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
JBrowse link
G ABCA1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression
EXP
ISO
[Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Sirolimus results in increased expression of ABCA1 mRNA
CTD PMID:17016853 PMID:21865292 NCBI chr 9:104,781,006...104,928,232
Ensembl chr 9:104,781,006...104,928,155
JBrowse link
G ABCB1 ATP binding cassette subfamily B member 1 affects metabolic processing
affects transport
EXP ABCB1 protein affects the metabolism of Sirolimus
ABCB1 protein affects the transport of Sirolimus
CTD PMID:15707415 PMID:15760093 PMID:15964407 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 decreases expression ISO Sirolimus results in decreased expression of ABCC2 mRNA CTD PMID:11589784 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC8 ATP binding cassette subfamily C member 8 decreases expression ISO Sirolimus results in decreased expression of ABCC8 mRNA CTD PMID:21865292 NCBI chr11:17,392,498...17,476,849
Ensembl chr11:17,392,498...17,476,879
JBrowse link
G ACADL acyl-CoA dehydrogenase long chain multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]] CTD PMID:25045214 NCBI chr 2:210,187,923...210,225,447
Ensembl chr 2:210,187,126...210,225,447
JBrowse link
G ACADM acyl-CoA dehydrogenase medium chain multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]] CTD PMID:25045214 NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,347...75,787,575
JBrowse link
G ACE2 angiotensin converting enzyme 2 decreases expression ISO Sirolimus results in decreased expression of ACE2 mRNA CTD PMID:21865292 NCBI chr  X:15,518,197...15,602,158
Ensembl chr  X:15,561,033...15,602,148
Ensembl chr  X:15,561,033...15,602,148
JBrowse link
G ACER2 alkaline ceramidase 2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] CTD PMID:21245298 NCBI chr 9:19,408,927...19,455,173
Ensembl chr 9:19,409,009...19,452,505
JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions EXP [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein CTD PMID:17908691 NCBI chr10:88,935,074...88,991,397
Ensembl chr10:88,935,074...88,991,339
JBrowse link
G ACTB actin beta increases expression
multiple interactions
ISO Sirolimus results in increased expression of ACTB mRNA
[Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA
CTD PMID:7503980 NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
Ensembl chr 7:5,526,409...5,563,902
JBrowse link
G AGT angiotensinogen multiple interactions ISO Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium] CTD PMID:21613610 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G AIFM1 apoptosis inducing factor mitochondria associated 1 decreases expression
multiple interactions
ISO
EXP
Sirolimus results in decreased expression of AIFM1 protein
[7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein]
CTD PMID:15767555 PMID:16497721 NCBI chr  X:130,129,362...130,165,841
Ensembl chr  X:130,124,666...130,165,879
Ensembl chr  X:130,124,666...130,165,879
JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
EXP
ISO
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Sirolimus co-treated with arsenic trioxide] results in decreased phosphorylation of AKT1 protein; arsenic trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]
Sirolimus affects the phosphorylation of AKT1 protein
resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]
[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein; Sirolimus results in increased phosphorylation of AKT1 protein
Sirolimus results in decreased phosphorylation of AKT1 protein
[Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Resveratrol results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]
CTD PMID:15806154 PMID:18495876 PMID:18622747 PMID:19176369 PMID:21092744 PMID:21976531 PMID:23000059 PMID:24299490 PMID:24304514 PMID:24392034 PMID:25597859 PMID:25758096 PMID:26282490 PMID:26369790 PMID:28108221 PMID:28342888 PMID:30905858 PMID:31499194 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G AKT1S1 AKT1 substrate 1 multiple interactions ISO [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of AKT1S1 protein; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of AKT1S1 protein
CTD PMID:24304514 NCBI chr19:49,869,033...49,878,356
Ensembl chr19:49,869,033...49,878,459
JBrowse link
G AKT2 AKT serine/threonine kinase 2 multiple interactions EXP [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein; Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein CTD PMID:17908691 NCBI chr19:40,230,317...40,285,531
Ensembl chr19:40,230,317...40,285,536
JBrowse link
G ANGPTL6 angiopoietin like 6 increases expression ISO Sirolimus results in increased expression of ANGPTL6 mRNA CTD PMID:21865292 NCBI chr19:10,092,338...10,106,407
Ensembl chr19:10,092,338...10,102,796
JBrowse link
G AOPEP aminopeptidase O (putative) multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA] CTD PMID:21245298 NCBI chr 9:94,726,669...95,148,264
Ensembl chr 9:94,726,701...95,087,218
Ensembl chr 9:94,726,701...95,087,218
JBrowse link
G APOD apolipoprotein D affects localization EXP Sirolimus affects the localization of APOD protein CTD PMID:28182653 NCBI chr 3:195,568,705...195,583,940
Ensembl chr 3:195,568,705...195,584,033
JBrowse link
G APP amyloid beta precursor protein decreases expression
increases expression
EXP
ISO
Sirolimus results in decreased expression of APP protein modified form
Sirolimus results in increased expression of APP protein modified form
CTD PMID:20542014 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
JBrowse link
G AQP2 aquaporin 2 multiple interactions
decreases expression
ISO rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of AQP2 protein] CTD PMID:19656910 NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878
JBrowse link
G AR androgen receptor multiple interactions
increases expression
increases activity
EXP [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus affects the reaction [Testosterone results in increased expression of AR protein]; Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein]
Sirolimus results in increased expression of AR protein
CTD PMID:18776922 PMID:21036700 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619
JBrowse link
G ASNS asparagine synthetase (glutamine-hydrolyzing) multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA] CTD PMID:11355896 NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
JBrowse link
G ATF3 activating transcription factor 3 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of ATF3 mRNA CTD PMID:25307878 NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein]
CTD PMID:24057571 PMID:29870746 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATG4A autophagy related 4A cysteine peptidase increases expression ISO Sirolimus results in increased expression of ATG4A mRNA CTD PMID:21681844 NCBI chr  X:108,091,778...108,154,671
Ensembl chr  X:108,091,668...108,154,671
JBrowse link
G ATG4B autophagy related 4B cysteine peptidase increases expression ISO Sirolimus results in increased expression of ATG4B mRNA CTD PMID:21681844 NCBI chr 2:241,637,659...241,673,857
Ensembl chr 2:241,637,213...241,673,857
JBrowse link
G ATG5 autophagy related 5 multiple interactions
increases expression
EXP
ISO
[Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]
Sirolimus results in increased expression of ATG5 protein
Sirolimus results in increased expression of ATG5 mRNA; Sirolimus results in increased expression of ATG5 protein
[Sirolimus co-treated with cadmium acetate] results in increased expression of ATG5 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]
CTD PMID:19682553 PMID:29128638 PMID:29505745 PMID:29870746 PMID:30338810 PMID:30611790 PMID:31676321 NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA CTD PMID:31676321 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G AURKB aurora kinase B multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA CTD PMID:19016759 NCBI chr17:8,204,731...8,210,767
Ensembl chr17:8,204,733...8,210,600
JBrowse link
G BAD BCL2 associated agonist of cell death multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA] CTD PMID:11355896 NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
JBrowse link
G BAX BCL2 associated X, apoptosis regulator affects localization
increases expression
multiple interactions
EXP
ISO
Sirolimus affects the localization of BAX protein
Sirolimus results in increased expression of BAX mRNA; Sirolimus results in increased expression of BAX protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein
[Curcumin co-treated with Sirolimus] results in increased expression of BAX; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BAX protein]
CTD PMID:11602639 PMID:15782132 PMID:19373661 PMID:19922502 PMID:29054700 PMID:30905858 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BBC3 BCL2 binding component 3 multiple interactions EXP [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] CTD PMID:19560264 PMID:20686837 NCBI chr19:47,220,822...47,232,998
Ensembl chr19:47,220,822...47,232,766
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
affects expression
decreases expression
EXP
ISO
[Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein]
Sirolimus affects the expression of BCL2 protein
Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein]
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA
Sirolimus results in decreased expression of BCL2 mRNA; Sirolimus results in decreased expression of BCL2 protein
CTD PMID:11355896 PMID:15571967 PMID:18640276 PMID:19373661 PMID:19764996 PMID:19815708 PMID:21410490 PMID:29054700 PMID:30905858 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions
increases expression
decreases expression
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein]
Sirolimus results in increased expression of BCL2L1 mRNA; Sirolimus results in increased expression of BCL2L1 protein
Sirolimus results in decreased expression of BCL2L1 mRNA; Sirolimus results in decreased expression of BCL2L1 protein
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]
CTD PMID:11355896 PMID:15767555 PMID:15782132 PMID:18097008 PMID:18789402 PMID:19922502 PMID:21681844 PMID:29054700 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G BCL2L11 BCL2 like 11 multiple interactions
decreases expression
increases expression
EXP
ISO
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA]
Sirolimus results in decreased expression of BCL2L11 protein
Sirolimus results in increased expression of BCL2L11 protein
CTD PMID:18097008 PMID:21092744 PMID:29054700 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,445
JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions ISO Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] CTD PMID:17209049 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
JBrowse link
G BECN1 beclin 1 multiple interactions
increases expression
EXP
ISO
[Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein]
[Sirolimus co-treated with cadmium acetate] results in increased expression of BECN1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [T-2 Toxin results in increased expression of BECN1 mRNA]
Sirolimus results in increased expression of BECN1 protein
Sirolimus results in increased expression of BECN1 mRNA; Sirolimus results in increased expression of BECN1 protein
CTD PMID:20358864 PMID:21410490 PMID:26648565 PMID:26825372 PMID:27107786 PMID:28025121 PMID:28888487 PMID:29505745 PMID:29518472 PMID:29870746 PMID:30555576 PMID:30611790 PMID:30629952 PMID:30905858 PMID:31676321 PMID:32306690 PMID:32430275 PMID:32645460 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BGLAP bone gamma-carboxyglutamate protein multiple interactions EXP Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] CTD PMID:23111315 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
JBrowse link
G BID BH3 interacting domain death agonist multiple interactions
increases expression
decreases expression
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein
Sirolimus results in increased expression of BID mRNA; Sirolimus results in increased expression of BID protein
Sirolimus results in decreased expression of BID protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein
CTD PMID:15767555 PMID:18097008 PMID:19922502 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
JBrowse link
G BIRC2 baculoviral IAP repeat containing 2 multiple interactions
increases expression
affects localization
EXP
ISO
Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein]
Sirolimus results in increased expression of BIRC2 protein
Sirolimus affects the localization of BIRC2 protein
CTD PMID:15571967 PMID:21357504 NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 multiple interactions
decreases expression
EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA; Sirolimus inhibits the reaction [N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide results in increased expression of and affects the localization of BIRC5 protein]; Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein]
Sirolimus results in decreased expression of BIRC5 protein
CTD PMID:19016759 PMID:19931998 PMID:21601561 PMID:24444656 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G BMP2 bone morphogenetic protein 2 multiple interactions EXP Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] CTD PMID:23111315 NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
JBrowse link
G BNIP3 BCL2 interacting protein 3 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA] CTD PMID:11355896 NCBI chr10:131,967,683...131,982,013
Ensembl chr10:131,966,455...131,982,013
JBrowse link
G BTBD11 BTB domain containing 11 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA] CTD PMID:21245298 NCBI chr12:107,316,749...107,659,642
Ensembl chr12:107,318,421...107,659,642
JBrowse link
G BTC betacellulin multiple interactions ISO Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein] CTD PMID:19105244 NCBI chr 4:74,744,759...74,794,718
Ensembl chr 4:74,744,759...74,794,523
JBrowse link
G BTK Bruton tyrosine kinase multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA] CTD PMID:11355896 NCBI chr  X:101,349,450...101,390,796
Ensembl chr  X:101,349,447...101,390,796
JBrowse link
G BUB1 BUB1 mitotic checkpoint serine/threonine kinase multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA CTD PMID:19016759 NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063
JBrowse link
G BUB1B BUB1 mitotic checkpoint serine/threonine kinase B multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA CTD PMID:19016759 NCBI chr15:40,161,069...40,221,123
Ensembl chr15:40,161,023...40,221,136
Ensembl chr15:40,161,023...40,221,136
JBrowse link
G C1QA complement C1q A chain decreases expression ISO Sirolimus results in decreased expression of C1QA mRNA CTD PMID:21865292 NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,636,628...22,639,678
JBrowse link
G C1QC complement C1q C chain decreases expression ISO Sirolimus results in decreased expression of C1QC mRNA CTD PMID:21865292 NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,633...22,648,110
JBrowse link
G C3 complement C3 decreases expression ISO Sirolimus results in decreased expression of C3 mRNA CTD PMID:21865292 NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
JBrowse link
G CALD1 caldesmon 1 multiple interactions
increases expression
EXP [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein
Sirolimus results in increased expression of CALD1 protein
CTD PMID:17908691 NCBI chr 7:134,779,629...134,970,729
Ensembl chr 7:134,744,252...134,970,729
JBrowse link
G CAMK2A calcium/calmodulin dependent protein kinase II alpha multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] CTD PMID:21933187 NCBI chr 5:150,219,491...150,290,130
Ensembl chr 5:150,219,491...150,290,291
JBrowse link
G CAPN1 calpain 1 decreases activity ISO Sirolimus results in decreased activity of CAPN1 protein CTD PMID:21357504 NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
JBrowse link
G CASP1 caspase 1 multiple interactions EXP
ISO
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]
CTD PMID:30205151 PMID:31586597 NCBI chr11:105,025,443...105,035,591
Ensembl chr11:105,025,443...105,035,250
JBrowse link
G CASP12 caspase 12 (gene/pseudogene) decreases cleavage
multiple interactions
ISO Sirolimus results in decreased cleavage of CASP12 protein
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of CASP12 protein]
CTD PMID:20511674 PMID:29870746 NCBI chr11:104,885,718...104,898,460
Ensembl chr11:104,885,718...104,898,670
JBrowse link
G CASP2 caspase 2 multiple interactions EXP [Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] CTD PMID:15767555 NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
JBrowse link
G CASP3 caspase 3 multiple interactions
increases expression
decreases activity
increases activity
increases cleavage
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA]
Sirolimus results in increased expression of CASP3 protein modified form
Sirolimus inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus promotes the reaction [Cadmium results in increased cleavage of CASP3 protein]
Sirolimus results in decreased activity of CASP3 protein
[Sirolimus co-treated with Resveratrol] results in increased cleavage of CASP3 protein; Sirolimus inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; Sirolimus promotes the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus results in decreased cleavage of and results in decreased activity of CASP3 protein
Sirolimus results in increased expression of CASP3 mRNA; Sirolimus results in increased expression of CASP3 protein
Sirolimus results in increased activity of CASP3 protein
Sirolimus results in increased cleavage of CASP3 protein
CTD PMID:14502240 PMID:15571967 PMID:15753396 PMID:15767555 PMID:15782132 PMID:15878982 PMID:16497721 PMID:18058806 PMID:18097008 PMID:19373661 PMID:19682553 PMID:19764996 PMID:20031680 PMID:20358864 PMID:21357504 PMID:21410490 PMID:21681844 PMID:24299490 PMID:24304514 PMID:26588882 PMID:26825372 PMID:28342888 PMID:29111403 PMID:30030080 PMID:30236763 PMID:30629952 PMID:31676321 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP7 caspase 7 multiple interactions
decreases activity
EXP
ISO
[Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein
Sirolimus results in decreased activity of CASP7 protein
CTD PMID:15753396 PMID:19373661 PMID:20031680 NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
JBrowse link
G CASP8 caspase 8 multiple interactions
increases cleavage
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein]
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]
Sirolimus results in increased cleavage of CASP8 protein
CTD PMID:15767555 PMID:17121904 PMID:18058806 PMID:25307878 PMID:28342888 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CASP9 caspase 9 multiple interactions
decreases activity
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]
Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein]
Sirolimus results in decreased activity of CASP9 protein
CTD PMID:15753396 PMID:15767555 PMID:16497721 PMID:17121904 PMID:18058806 PMID:18097008 PMID:19373661 PMID:20138251 PMID:28342888 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase increases expression ISO Sirolimus results in increased expression of CAT protein CTD PMID:30905858 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CAV3 caveolin 3 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] CTD PMID:21245298 NCBI chr 3:8,733,802...8,746,758
Ensembl chr 3:8,733,802...8,841,808
Ensembl chr 3:8,733,802...8,841,808
JBrowse link
G CCN2 cellular communication network factor 2 increases expression ISO Sirolimus results in increased expression of CCN2 mRNA CTD PMID:21865292 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
JBrowse link
G CCNA2 cyclin A2 multiple interactions
decreases expression
EXP
ISO
[fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA
Sirolimus results in decreased expression of CCNA2 protein
Sirolimus results in decreased expression of CCNA2; Sirolimus results in decreased expression of CCNA2 protein
CTD PMID:7503980 PMID:8419408 PMID:19016759 PMID:19505958 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
JBrowse link
G CCNB2 cyclin B2 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA CTD PMID:19016759 NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045
JBrowse link
G CCND1 cyclin D1 multiple interactions
decreases expression
increases expression
increases degradation
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1; [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus co-treated with letrozole] results in decreased expression of CCND1 protein; [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]
Sirolimus results in increased degradation of CCND1 protein
CTD PMID:7532117 PMID:15753396 PMID:15767555 PMID:17121904 PMID:19105244 PMID:19505958 PMID:19661225 PMID:20054642 PMID:23006739 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CCND2 cyclin D2 multiple interactions
decreases expression
EXP
ISO
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]
Sirolimus results in decreased expression of CCND2 protein
Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA]
CTD PMID:15070696 PMID:15778701 PMID:17510244 NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
Ensembl chr12:4,269,771...4,305,353
JBrowse link
G CCND3 cyclin D3 multiple interactions
decreases expression
decreases stability
EXP
ISO
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]
Sirolimus results in decreased expression of CCND3 mRNA; Sirolimus results in decreased expression of CCND3 protein
Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]
Sirolimus results in decreased stability of CCND3 mRNA
CTD PMID:10849422 PMID:12393642 PMID:15070696 PMID:15778701 PMID:15882288 NCBI chr 6:41,934,933...42,048,894
Ensembl chr 6:41,934,933...42,050,357
Ensembl chr 6:41,934,933...42,050,357
JBrowse link
G CCNE2 cyclin E2 multiple interactions EXP [Fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] CTD PMID:19016759 PMID:27542212 NCBI chr 8:94,880,224...94,896,671
Ensembl chr 8:94,879,770...94,896,678
JBrowse link
G CCNG2 cyclin G2 multiple interactions
increases expression
EXP [cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]
Sirolimus results in increased expression of CCNG2 mRNA
CTD PMID:18754885 PMID:21245298 PMID:24356939 PMID:27542212 NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
JBrowse link
G CCNI cyclin I multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA] CTD PMID:11355896 NCBI chr 4:77,047,155...77,075,989
Ensembl chr 4:77,047,155...77,076,309
Ensembl chr 4:77,047,155...77,076,309
JBrowse link
G CD36 CD36 molecule affects expression
multiple interactions
EXP Sirolimus affects the expression of CD36 protein
Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA]
CTD PMID:17016853 PMID:19640849 NCBI chr 7:80,602,207...80,679,277
Ensembl chr 7:80,369,575...80,679,277
JBrowse link
G CD38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 PMID:24445604 NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232
JBrowse link
G CD68 CD68 molecule decreases expression EXP
ISO
Sirolimus results in decreased expression of CD68 mRNA CTD PMID:17016853 PMID:21865292 NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111
JBrowse link
G CD80 CD80 molecule decreases expression ISO Sirolimus results in decreased expression of CD80 protein CTD PMID:12531798 NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614
JBrowse link
G CD84 CD84 molecule increases expression EXP Sirolimus results in increased expression of CD84 mRNA CTD PMID:24356939 NCBI chr 1:160,541,098...160,579,515
Ensembl chr 1:160,541,095...160,579,516
JBrowse link
G CD86 CD86 molecule decreases expression ISO Sirolimus results in decreased expression of CD86 protein CTD PMID:12531798 NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139
JBrowse link
G CDC20 cell division cycle 20 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA CTD PMID:19016759 NCBI chr 1:43,358,981...43,363,203
Ensembl chr 1:43,358,981...43,363,203
JBrowse link
G CDH1 cadherin 1 increases expression
multiple interactions
EXP
ISO
Sirolimus results in increased expression of CDH1 protein
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]
Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]
CTD PMID:28624451 PMID:28888487 PMID:30053495 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,541
JBrowse link
G CDH2 cadherin 2 multiple interactions ISO Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] CTD PMID:30053495 NCBI chr18:27,932,878...28,177,130
Ensembl chr18:27,932,879...28,177,946
Ensembl chr18:27,932,879...28,177,946
JBrowse link
G CDK1 cyclin dependent kinase 1 multiple interactions
decreases activity
decreases expression
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein; [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA
Sirolimus results in decreased activity of CDK1 protein
Sirolimus results in decreased expression of CDK1 mRNA; Sirolimus results in decreased expression of CDK1 protein
Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]
CTD PMID:7503980 PMID:7532117 PMID:8419408 PMID:11355896 PMID:15767555 PMID:19016759 PMID:19223503 PMID:19922502 NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
JBrowse link
G CDK2 cyclin dependent kinase 2 multiple interactions
decreases activity
EXP
ISO
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]
Sirolimus results in decreased activity of CDK2 protein
CTD PMID:7532117 PMID:12393642 PMID:12417722 PMID:14979923 PMID:21528311 NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
JBrowse link
G CDK4 cyclin dependent kinase 4 decreases expression EXP Sirolimus results in decreased expression of CDK4 protein CTD PMID:22761470 NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions
decreases expression
increases expression
EXP
ISO
[(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A mRNA; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA]; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A mRNA]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA]
Sirolimus results in decreased expression of CDKN1A protein
Sirolimus results in increased expression of CDKN1A mRNA; Sirolimus results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
CTD PMID:12417722 PMID:14979923 PMID:17700525 PMID:19105244 PMID:19764996 PMID:21528311 PMID:22561310 PMID:25307878 PMID:30555576 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,339
Ensembl chr 6:36,676,460...36,687,339
JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression
decreases degradation
EXP
ISO
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA]
Sirolimus results in decreased expression of CDKN1B protein
Sirolimus results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]
Sirolimus results in decreased degradation of CDKN1B protein
CTD PMID:12417722 PMID:12565877 PMID:14979923 PMID:15070696 PMID:16455087 PMID:18622747 PMID:19105244 PMID:21092744 PMID:22561310 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,715,058...12,722,369
JBrowse link
G CDX2 caudal type homeobox 2 increases expression ISO Sirolimus results in increased expression of CDX2 mRNA CTD PMID:21681844 NCBI chr13:27,960,918...27,969,337
Ensembl chr13:27,960,918...27,969,315
JBrowse link
G CEBPA CCAAT enhancer binding protein alpha decreases expression ISO Sirolimus results in decreased expression of CEBPA mRNA CTD PMID:15358118 NCBI chr19:33,299,934...33,302,564
Ensembl chr19:33,299,934...33,302,534
JBrowse link
G CENPX centromere protein X increases expression ISO Sirolimus results in increased expression of CENPX mRNA CTD PMID:11355896 NCBI chr17:82,018,703...82,022,930
Ensembl chr17:82,018,702...82,024,107
JBrowse link
G CFD complement factor D decreases expression ISO Sirolimus results in decreased expression of CFD mRNA CTD PMID:15358118 NCBI chr19:859,664...863,641
Ensembl chr19:859,664...863,641
JBrowse link
G CHRNB3 cholinergic receptor nicotinic beta 3 subunit multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] CTD PMID:21245298 NCBI chr 8:42,697,366...42,737,407
Ensembl chr 8:42,697,366...42,737,407
JBrowse link
G CIDEC cell death inducing DFFA like effector c multiple interactions ISO Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] CTD PMID:31499194 NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255
Ensembl chr 3:9,866,711...9,880,255
JBrowse link
G CKS1B CDC28 protein kinase regulatory subunit 1B decreases expression ISO Sirolimus results in decreased expression of CKS1B mRNA CTD PMID:11355896 NCBI chr 1:154,974,681...154,979,251
Ensembl chr 1:154,974,653...154,979,251
JBrowse link
G CLDN7 claudin 7 increases expression ISO Sirolimus results in increased expression of CLDN7 mRNA CTD PMID:21865292 NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983
JBrowse link
G CLEC4A C-type lectin domain family 4 member A decreases expression ISO Sirolimus results in decreased expression of CLEC4A mRNA CTD PMID:21865292 NCBI chr12:8,102,902...8,138,607
Ensembl chr12:8,123,632...8,138,607
JBrowse link
G COL1A1 collagen type I alpha 1 chain decreases expression ISO Sirolimus results in decreased expression of COL1A1 mRNA CTD PMID:21865292 NCBI chr17:50,184,096...50,201,649
Ensembl chr17:50,183,289...50,201,632
Ensembl chr17:50,183,289...50,201,632
JBrowse link
G COL1A2 collagen type I alpha 2 chain multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA]
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]
CTD PMID:10535884 PMID:11343241 NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
JBrowse link
G CP ceruloplasmin increases expression ISO Sirolimus results in increased expression of CP mRNA CTD PMID:21865292 NCBI chr 3:149,162,410...149,222,008
Ensembl chr 3:149,162,410...149,221,829
JBrowse link
G CPT1B carnitine palmitoyltransferase 1B multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]] CTD PMID:25045214 NCBI chr22:50,568,861...50,578,612
Ensembl chr22:50,568,861...50,578,465
JBrowse link
G CPT2 carnitine palmitoyltransferase 2 multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]] CTD PMID:25045214 NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197
JBrowse link
G CREB1 cAMP responsive element binding protein 1 multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]] CTD PMID:22363816 NCBI chr 2:207,529,943...207,605,988
Ensembl chr 2:207,529,737...207,605,988
JBrowse link
G CREBRF CREB3 regulatory factor multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CREBRF mRNA CTD PMID:25307878 NCBI chr 5:173,056,349...173,139,284
Ensembl chr 5:173,056,352...173,139,284
JBrowse link
G CRTC2 CREB regulated transcription coactivator 2 decreases activity EXP Sirolimus results in decreased activity of CRTC2 protein CTD PMID:23440206 NCBI chr 1:153,947,675...153,958,643
Ensembl chr 1:153,947,669...153,958,615
JBrowse link
G CSE1L chromosome segregation 1 like decreases expression ISO Sirolimus results in decreased expression of CSE1L mRNA CTD PMID:11355896 NCBI chr20:49,046,312...49,096,949
Ensembl chr20:49,046,246...49,096,960
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions ISO Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions ISO Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]] CTD PMID:1376361 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions ISO Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] CTD PMID:30053495 NCBI chr 3:41,199,422...41,240,445
Ensembl chr 3:41,194,741...41,260,096
JBrowse link
G CTSK cathepsin K multiple interactions
decreases expression
ISO PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased activity of CTSK protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]
Sirolimus results in decreased expression of CTSK mRNA
CTD PMID:26369790 NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,796,208...150,808,260
Ensembl chr 1:150,796,208...150,808,260
JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 decreases expression ISO Sirolimus results in decreased expression of CXCL10 mRNA CTD PMID:21865292 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
JBrowse link
G CXCL13 C-X-C motif chemokine ligand 13 decreases expression ISO Sirolimus results in decreased expression of CXCL13 mRNA CTD PMID:21865292 NCBI chr 4:77,511,753...77,611,834
Ensembl chr 4:77,511,753...77,611,834
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions
increases expression
EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CXCL8 mRNA; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]
Sirolimus results in increased expression of CXCL8 mRNA
CTD PMID:17606477 PMID:25307878 PMID:27542212 PMID:29594315 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,541...73,743,716
JBrowse link
G CYBA cytochrome b-245 alpha chain multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] CTD PMID:21195169 NCBI chr16:88,643,289...88,651,079
Ensembl chr16:88,643,289...88,651,054
JBrowse link
G CYBB cytochrome b-245 beta chain multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] CTD PMID:21195169 NCBI chr  X:37,780,059...37,813,461
Ensembl chr  X:37,780,059...37,813,461
Ensembl chr  X:37,780,059...37,813,461
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 multiple interactions
decreases activity
EXP [Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein
Sirolimus results in decreased activity of CYP27A1 protein
CTD PMID:17516993 NCBI chr 2:218,781,733...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP2A6 cytochrome P450 family 2 subfamily A member 6 decreases expression EXP Sirolimus results in decreased expression of CYP2A6 protein CTD PMID:25929522 NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 increases expression EXP Sirolimus results in increased expression of CYP2B6 mRNA CTD PMID:25929522 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 decreases expression
increases expression
EXP Sirolimus results in decreased expression of CYP2C9 protein
Sirolimus results in increased expression of CYP2C9 mRNA
CTD PMID:25929522 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 affects metabolic processing EXP CYP3A4 protein affects the metabolism of Sirolimus; CYP3A4 protein polymorphism affects the metabolism of Sirolimus CTD PMID:15707415 PMID:15964407 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of DDIT3 protein]
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of DDIT3 mRNA; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA]; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]
CTD PMID:11145585 PMID:19420259 PMID:21321189 PMID:22215663 PMID:25307878 PMID:29870746 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DDIT4L DNA damage inducible transcript 4 like decreases expression
increases expression
ISO Sirolimus results in decreased expression of DDIT4L mRNA
Sirolimus results in increased expression of DDIT4L mRNA
CTD PMID:21865292 NCBI chr 4:100,185,870...100,190,468
Ensembl chr 4:100,185,870...100,190,782
JBrowse link
G DEPTOR DEP domain containing MTOR interacting protein multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA] CTD PMID:21245298 NCBI chr 8:119,873,722...120,050,918
Ensembl chr 8:119,873,717...120,050,918
JBrowse link
G DIABLO diablo IAP-binding mitochondrial protein multiple interactions EXP [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] CTD PMID:15767555 NCBI chr12:122,207,662...122,227,456
Ensembl chr12:122,207,663...122,227,456
Ensembl chr12:122,207,663...122,227,456
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 decreases expression ISO Sirolimus results in decreased expression of DNAJC6 mRNA CTD PMID:21865292 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNMT1 DNA methyltransferase 1 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA CTD PMID:19016759 NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,345...10,231,286
Ensembl chr19:10,133,345...10,231,286
JBrowse link
G DPYD dihydropyrimidine dehydrogenase decreases expression EXP Sirolimus results in decreased expression of DPYD mRNA CTD PMID:19764996 NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000
JBrowse link
G DUSP10 dual specificity phosphatase 10 increases expression EXP Sirolimus results in increased expression of DUSP10 mRNA CTD PMID:24356939 NCBI chr 1:221,701,424...221,742,091
Ensembl chr 1:221,701,424...221,742,089
JBrowse link
G DUSP15 dual specificity phosphatase 15 decreases expression ISO Sirolimus results in decreased expression of DUSP15 mRNA CTD PMID:21865292 NCBI chr20:31,845,578...31,870,664
Ensembl chr20:31,847,637...31,870,747
JBrowse link
G E2F1 E2F transcription factor 1 multiple interactions EXP
ISO
[TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein CTD PMID:12417722 NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
JBrowse link
G E2F4 E2F transcription factor 4 multiple interactions EXP [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr16:67,192,155...67,198,918
Ensembl chr16:67,192,155...67,198,918
JBrowse link
G EDN1 endothelin 1 multiple interactions ISO Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:12411397 NCBI chr 6:12,256,463...12,297,194
Ensembl chr 6:12,290,361...12,297,194
JBrowse link
G EEF2 eukaryotic translation elongation factor 2 increases phosphorylation EXP Sirolimus results in increased phosphorylation of EEF2 protein CTD PMID:25940091 NCBI chr19:3,976,056...3,985,463
Ensembl chr19:3,976,056...3,985,463
JBrowse link
G EGF epidermal growth factor multiple interactions
decreases activity
EXP
ISO
Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]
Sirolimus analog results in decreased activity of EGF protein
CTD PMID:12406821 PMID:21187475 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
JBrowse link
G EGFR epidermal growth factor receptor multiple interactions ISO
EXP
[Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]; Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein CTD PMID:19151764 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G EIF2S1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO Sirolimus inhibits the reaction [cadmium acetate results in increased phosphorylation of EIF2S1 protein] CTD PMID:29870746 NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,151...67,386,516
Ensembl chr14:67,360,151...67,386,516
JBrowse link
G EIF4B eukaryotic translation initiation factor 4B multiple interactions
decreases phosphorylation
ISO
EXP
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of EIF4B protein; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]
Sirolimus results in decreased phosphorylation of EIF4B protein
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of EIF4B protein
CTD PMID:21268130 PMID:24304514 PMID:24375594 NCBI chr12:53,006,456...53,042,215
Ensembl chr12:53,006,282...53,042,215
Ensembl chr12:53,006,282...53,042,215
JBrowse link
G EIF4E eukaryotic translation initiation factor 4E multiple interactions
increases phosphorylation
decreases activity
EXP
ISO
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]
Sirolimus results in increased phosphorylation of EIF4E protein
Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4E protein]
Sirolimus results in decreased activity of EIF4E protein
CTD PMID:15757502 PMID:19560264 PMID:26282490 NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,871,684...98,930,637
JBrowse link
G EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
affects phosphorylation
decreases phosphorylation
EXP
ISO
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]
Sirolimus affects the phosphorylation of EIF4EBP1 protein
Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4EBP1 protein]
Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein; Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein]
CTD PMID:8599949 PMID:8971030 PMID:11909977 PMID:12411397 PMID:12939469 PMID:14502240 PMID:14673156 PMID:15782132 PMID:15806154 PMID:16255777 PMID:16597595 PMID:16962100 PMID:18021293 PMID:18058806 PMID:18622747 PMID:19478560 PMID:19560264 PMID:19853261 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21321189 PMID:21898527 PMID:21933187 PMID:22869613 PMID:23363784 PMID:24299490 PMID:24375594 PMID:25940091 NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
JBrowse link
G EIF4G1 eukaryotic translation initiation factor 4 gamma 1 multiple interactions EXP Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA] CTD PMID:25940091 NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358
JBrowse link
G EIF4G2 eukaryotic translation initiation factor 4 gamma 2 increases expression EXP Sirolimus results in increased expression of EIF4G2 protein CTD PMID:18491231 NCBI chr11:10,797,046...10,808,926
Ensembl chr11:10,797,050...10,808,940
JBrowse link
G ENO2 enolase 2 multiple interactions
increases expression
ISO 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] CTD PMID:26676567 NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698
JBrowse link
G ERN1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO
EXP
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]
Sirolimus inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]
CTD PMID:24898257 PMID:32283200 NCBI chr17:64,039,142...64,132,469
Ensembl chr17:64,039,142...64,130,819
JBrowse link
G ERO1A endoplasmic reticulum oxidoreductase 1 alpha multiple interactions ISO Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] CTD PMID:19420259 NCBI chr14:52,639,915...52,695,750
Ensembl chr14:52,639,915...52,695,900
JBrowse link
G ESPL1 extra spindle pole bodies like 1, separase multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA CTD PMID:19016759 NCBI chr12:53,268,257...53,293,643
Ensembl chr12:53,268,299...53,293,638
Ensembl chr12:53,268,299...53,293,638
JBrowse link
G ESR1 estrogen receptor 1 increases expression
increases phosphorylation
EXP Sirolimus results in increased expression of ESR1 protein
Sirolimus results in increased phosphorylation of ESR1 protein
CTD PMID:19016759 NCBI chr 6:151,654,148...152,129,619
Ensembl chr 6:151,656,691...152,129,619
JBrowse link
G EVI2A ecotropic viral integration site 2A increases expression EXP Sirolimus results in increased expression of EVI2A mRNA CTD PMID:24356939 NCBI chr17:31,316,410...31,321,622
Ensembl chr17:31,316,410...31,321,749
Ensembl chr17:31,316,410...31,321,749
JBrowse link
G EWSR1 EWS RNA binding protein 1 decreases expression EXP Sirolimus results in decreased expression of EWSR1 protein mutant form CTD PMID:15782132 NCBI chr22:29,268,254...29,300,523
Ensembl chr22:29,268,009...29,300,525
JBrowse link
G F2 coagulation factor II, thrombin decreases expression ISO Sirolimus results in decreased expression of F2 mRNA CTD PMID:21865292 NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506
Ensembl chr11:46,719,196...46,739,506
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions
increases activity
EXP
ISO
Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus results in increased activity of F3 protein
CTD PMID:19567381 NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
JBrowse link
G FAS Fas cell surface death receptor decreases expression ISO Sirolimus results in decreased expression of FAS mRNA CTD PMID:15358118 NCBI chr10:88,968,429...89,017,059
Ensembl chr10:88,990,531...89,017,059
JBrowse link
G FASLG Fas ligand decreases secretion EXP Sirolimus results in decreased secretion of FASLG protein CTD PMID:11692113 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
JBrowse link
G FAXDC2 fatty acid hydroxylase domain containing 2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] CTD PMID:21245298 NCBI chr 5:154,817,018...154,850,683
Ensembl chr 5:154,818,492...154,859,252
JBrowse link
G FBLN1 fibulin 1 increases expression ISO Sirolimus results in increased expression of FBLN1 mRNA CTD PMID:21865292 NCBI chr22:45,502,883...45,601,135
Ensembl chr22:45,502,238...45,601,135
JBrowse link
G FBXO32 F-box protein 32 multiple interactions
increases expression
EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of FBXO32 mRNA; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]
Sirolimus results in increased expression of FBXO32 mRNA
CTD PMID:21245298 PMID:24356939 PMID:25307878 NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206
JBrowse link
G FBXO5 F-box protein 5 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA CTD PMID:19016759 NCBI chr 6:152,970,535...152,983,579
Ensembl chr 6:152,970,519...152,983,579
JBrowse link
G FCGR1A Fc fragment of IgG receptor Ia multiple interactions
decreases expression
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Sirolimus results in decreased expression of FCGR1A protein]; arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein] CTD PMID:25758096 NCBI chr 1:149,782,694...149,800,609
Ensembl chr 1:149,782,671...149,792,518
JBrowse link
G FGB fibrinogen beta chain decreases expression
increases expression
ISO Sirolimus results in decreased expression of FGB mRNA
Sirolimus results in increased expression of FGB mRNA
CTD PMID:21865292 NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
Ensembl chr 4:154,563,011...154,572,807
JBrowse link
G FGF1 fibroblast growth factor 1 multiple interactions ISO [Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of FGF1 mRNA; Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 PMID:31332898 NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070
JBrowse link
G FGF21 fibroblast growth factor 21 multiple interactions ISO Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of FGF21 mRNA] CTD PMID:31499194 NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333
JBrowse link
G FGF7 fibroblast growth factor 7 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] CTD PMID:21245298 NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775
Ensembl chr15:49,423,237...49,488,775
JBrowse link
G FKBP1A FKBP prolyl isomerase 1A affects binding
multiple interactions
EXP
ISO
Sirolimus binds to FKBP1A protein
immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein]
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein; [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA; immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein]
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]
CTD PMID:7503980 PMID:7532117 PMID:10361256 PMID:12417722 PMID:12531798 PMID:17438408 NCBI chr20:1,368,977...1,393,172
Ensembl chr20:1,368,978...1,393,172
Ensembl chr20:1,368,978...1,393,172
JBrowse link
G FLT3LG fms related receptor tyrosine kinase 3 ligand decreases activity ISO Sirolimus results in decreased activity of FLT3LG protein CTD PMID:12531798 NCBI chr19:49,474,172...49,487,037
Ensembl chr19:49,474,207...49,486,231
JBrowse link
G FOLR1 folate receptor alpha multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] CTD PMID:21245298 NCBI chr11:72,189,709...72,196,323
Ensembl chr11:72,189,558...72,196,323
JBrowse link
G FOXM1 forkhead box M1 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA CTD PMID:19016759 NCBI chr12:2,857,680...2,877,174
Ensembl chr12:2,857,681...2,877,155
Ensembl chr12:2,857,681...2,877,155
JBrowse link
G FOXO1 forkhead box O1 increases phosphorylation EXP Sirolimus results in increased phosphorylation of FOXO1 protein CTD PMID:16227402 NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
JBrowse link
G FOXO3 forkhead box O3 multiple interactions
increases phosphorylation
EXP [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3 protein]; Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3 protein CTD PMID:21092744 NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
JBrowse link
G FOXP1 forkhead box P1 decreases expression EXP Sirolimus results in decreased expression of FOXP1 protein CTD PMID:25663935 NCBI chr 3:70,954,708...71,583,983
Ensembl chr 3:70,952,817...71,583,993
Ensembl chr 3:70,952,817...71,583,993
Ensembl chr 3:70,952,817...71,583,993
JBrowse link
G FOXP3 forkhead box P3 multiple interactions
increases expression
EXP
ISO
[TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
Sirolimus results in increased expression of FOXP3 mRNA
CTD PMID:20844194 NCBI chr  X:49,250,436...49,264,932
Ensembl chr  X:49,250,438...49,270,477
Ensembl chr  X:49,250,438...49,270,477
JBrowse link
G FRAT1 FRAT regulator of WNT signaling pathway 1 increases expression EXP Sirolimus results in increased expression of FRAT1 mRNA CTD PMID:24356939 NCBI chr10:97,319,271...97,321,915
Ensembl chr10:97,319,271...97,321,915
JBrowse link
G FSHB follicle stimulating hormone subunit beta multiple interactions ISO Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] CTD PMID:17510244 NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,016...30,235,261
Ensembl chr11:30,231,016...30,235,261
JBrowse link
G FTL ferritin light chain multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] CTD PMID:21245298 NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879
JBrowse link
G GABARAP GABA type A receptor-associated protein increases expression ISO Sirolimus results in increased expression of GABARAP mRNA CTD PMID:21681844 NCBI chr17:7,240,008...7,242,449
Ensembl chr17:7,240,008...7,242,449
JBrowse link
G GABARAPL1 GABA type A receptor associated protein like 1 multiple interactions ISO Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein CTD PMID:15888080 NCBI chr12:10,212,877...10,223,128
Ensembl chr12:10,212,458...10,223,128
JBrowse link
G GCM2 glial cells missing transcription factor 2 multiple interactions EXP Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] CTD PMID:21245298 NCBI chr 6:10,873,223...10,882,041
Ensembl chr 6:10,873,223...10,882,041
Ensembl chr 6:10,873,223...10,882,041
JBrowse link
G GEM GTP binding protein overexpressed in skeletal muscle multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of GEM mRNA CTD PMID:25307878 NCBI chr 8:94,249,249...94,262,345
Ensembl chr 8:94,249,253...94,262,350
JBrowse link
G GGT1 gamma-glutamyltransferase 1 multiple interactions ISO Sirolimus promotes the reaction [Cyclosporine affects the expression of GGT1 protein] CTD PMID:11589784 NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,556,007...24,628,987
Ensembl chr22:24,556,007...24,628,987
Ensembl chr22:24,556,007...24,628,987
JBrowse link
G GLB1 galactosidase beta 1 multiple interactions
decreases expression
ISO Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Sirolimus results in decreased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 3:32,996,617...33,097,146
Ensembl chr 3:32,996,609...33,097,202
JBrowse link
G GPER1 G protein-coupled estrogen receptor 1 multiple interactions EXP Sirolimus inhibits the reaction [puerarin results in increased expression of GPER1 protein] CTD PMID:27796870 NCBI chr 7:1,087,118...1,093,810
Ensembl chr 7:1,082,208...1,093,815
JBrowse link
G GPNMB glycoprotein nmb increases expression ISO Sirolimus results in increased expression of GPNMB mRNA CTD PMID:21865292 NCBI chr 7:23,246,766...23,275,110
Ensembl chr 7:23,235,967...23,275,108
JBrowse link
G GPR18 G protein-coupled receptor 18 increases expression EXP Sirolimus results in increased expression of GPR18 mRNA CTD PMID:24356939 NCBI chr13:99,254,713...99,262,498
Ensembl chr13:99,254,714...99,261,744
JBrowse link
G GPT glutamic--pyruvic transaminase multiple interactions ISO Sirolimus promotes the reaction [Cyclosporine affects the expression of GPT protein]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased activity of GPT protein]]
CTD PMID:11589784 PMID:31499194 NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions
increases activity
EXP
ISO
[3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]
CTD PMID:15753396 PMID:17908691 PMID:18495876 NCBI chr 3:119,821,321...120,095,823
Ensembl chr 3:119,821,323...120,094,417
Ensembl chr 3:119,821,323...120,094,417
Ensembl chr 3:119,821,323...120,094,417
JBrowse link
G GSTT1 glutathione S-transferase theta 1 increases response to substance EXP GSTT1 gene mutant form results in increased susceptibility to Sirolimus CTD PMID:12916871
G GTPBP4 GTP binding protein 4 decreases expression ISO Sirolimus results in decreased expression of GTPBP4 mRNA CTD PMID:21865292 NCBI chr10:988,434...1,019,932
Ensembl chr10:988,434...1,019,932
JBrowse link
G GUCA2A guanylate cyclase activator 2A increases expression ISO Sirolimus results in increased expression of GUCA2A mRNA CTD PMID:21865292 NCBI chr 1:42,162,690...42,164,745
Ensembl chr 1:42,162,690...42,164,745
JBrowse link
G GZMB granzyme B decreases expression EXP Sirolimus results in decreased expression of GZMB protein CTD PMID:16477233 NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267
JBrowse link
G H2AX H2A.X variant histone decreases expression EXP Sirolimus results in decreased expression of H2AX protein CTD PMID:23363784 NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,854...119,095,467
JBrowse link
G HAVCR1 hepatitis A virus cellular receptor 1 increases expression ISO Sirolimus results in increased expression of HAVCR1 mRNA CTD PMID:21865292 NCBI chr 5:157,028,383...157,069,633
Ensembl chr 5:157,029,413...157,059,119
JBrowse link
G HBP1 HMG-box transcription factor 1 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of HBP1 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] CTD PMID:25307878 PMID:27542212 NCBI chr 7:107,168,987...107,202,523
Ensembl chr 7:107,168,961...107,202,522
JBrowse link
G HES1 hes family bHLH transcription factor 1 decreases expression EXP
ISO
Sirolimus results in decreased expression of HES1 protein
Sirolimus results in decreased expression of HES1 mRNA; Sirolimus results in decreased expression of HES1 protein
CTD PMID:20038814 NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732
JBrowse link
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions
decreases expression
EXP
ISO
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein]
Sirolimus results in decreased expression of HIF1A mRNA
Sirolimus results in decreased expression of HIF1A protein
CTD PMID:15050414 PMID:15297429 PMID:15634505 PMID:16682453 PMID:17968710 PMID:19335982 PMID:19640849 PMID:20335389 PMID:20554536 PMID:21984483 PMID:28574600 NCBI chr14:61,695,513...61,748,259
Ensembl chr14:61,695,513...61,748,259
JBrowse link
G HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase increases expression EXP Sirolimus results in increased expression of HMGCR mRNA CTD PMID:17516993 NCBI chr 5:75,336,334...75,362,116
Ensembl chr 5:75,336,329...75,362,101
JBrowse link
G HMOX1 heme oxygenase 1 increases expression
multiple interactions
ISO Sirolimus results in increased expression of HMOX1
Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]
CTD PMID:17003813 PMID:19420259 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HNRNPD heterogeneous nuclear ribonucleoprotein D decreases expression
increases expression
EXP
ISO
Sirolimus results in decreased expression of HNRNPD protein
Sirolimus results in increased expression of HNRNPD protein
CTD PMID:17603996 NCBI chr 4:82,352,498...82,373,991
Ensembl chr 4:82,352,498...82,374,503
JBrowse link
G HOXA9 homeobox A9 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] CTD PMID:21245298 NCBI chr 7:27,162,438...27,165,537
Ensembl chr 7:27,162,438...27,175,180
JBrowse link
G HRAS HRas proto-oncogene, GTPase multiple interactions ISO
EXP
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR193A-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-2 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]
CTD PMID:24898257 PMID:30619488 NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,287
JBrowse link
G HSPA1B heat shock protein family A (Hsp70) member 1B decreases expression EXP Sirolimus results in decreased expression of HSPA1B mRNA CTD PMID:24356939 NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 decreases expression
multiple interactions
EXP
ISO
Sirolimus results in decreased expression of HSPA5 mRNA
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein]
[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
CTD PMID:24356939 PMID:24898257 PMID:29870746 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 decreases expression EXP Sirolimus results in decreased expression of HSPB8 protein CTD PMID:21233418 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G IBSP integrin binding sialoprotein multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] CTD PMID:31051157 NCBI chr 4:87,799,554...87,812,435
Ensembl chr 4:87,799,554...87,812,435
JBrowse link
G ICAM1 intercellular adhesion molecule 1 decreases expression ISO Sirolimus results in decreased expression of ICAM1 protein CTD PMID:12531798 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G ID1 inhibitor of DNA binding 1, HLH protein increases expression EXP Sirolimus results in increased expression of ID1 mRNA CTD PMID:23824090 PMID:24356939 NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515
JBrowse link
G IFNG interferon gamma multiple interactions
decreases secretion
EXP
ISO
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]
Sirolimus results in decreased secretion of IFNG protein
CTD PMID:11692113 PMID:16427044 PMID:21600178 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions
increases response to substance
EXP
ISO
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]
Sirolimus results in increased susceptibility to IGF1 protein
Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]
CTD PMID:11355896 PMID:15070696 PMID:15297429 PMID:16227402 PMID:16682453 PMID:17908691 PMID:19105244 PMID:25597859 NCBI chr12:102,395,860...102,481,839
Ensembl chr12:102,395,874...102,481,744
JBrowse link
G IGF1R insulin like growth factor 1 receptor affects activity
multiple interactions
EXP Sirolimus affects the activity of IGF1R protein
Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]
CTD PMID:16227402 NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 increases expression ISO Sirolimus results in increased expression of IGFBP1 mRNA CTD PMID:21865292 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
JBrowse link
G IGFBP3 insulin like growth factor binding protein 3 multiple interactions EXP Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] CTD PMID:16682453 NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
JBrowse link
G IGFBP5 insulin like growth factor binding protein 5 decreases expression ISO Sirolimus results in decreased expression of IGFBP5 mRNA CTD PMID:21865292 NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549
JBrowse link
G IL10 interleukin 10 multiple interactions
decreases expression
EXP
ISO
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein]
Sirolimus results in decreased expression of IL10 mRNA
Sirolimus results in decreased expression of IL10 protein
[Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]]
CTD PMID:11169223 PMID:15588918 PMID:31499194 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G IL12A interleukin 12A multiple interactions ISO Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019
JBrowse link
G IL12B interleukin 12B multiple interactions ISO Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,487
JBrowse link
G IL17RB interleukin 17 receptor B multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA CTD PMID:19016759 NCBI chr 3:53,846,550...53,867,388
Ensembl chr 3:53,846,568...53,865,794
JBrowse link
G IL18 interleukin 18 multiple interactions EXP Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] CTD PMID:30205151 NCBI chr11:112,143,251...112,164,104
Ensembl chr11:112,143,253...112,164,096
JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases expression
affects expression
ISO
EXP
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Sirolimus results in increased expression of IL1B mRNA
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]
Sirolimus results in increased expression of IL1B protein
Sirolimus affects the expression of IL1B mRNA
CTD PMID:22363816 PMID:23211629 PMID:24971338 PMID:25045214 PMID:29594315 PMID:30205151 PMID:31499194 PMID:31586597 NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
JBrowse link
G IL2 interleukin 2 multiple interactions
affects expression
decreases response to substance
EXP
ISO
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]
Sirolimus affects the expression of IL2 protein
[Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
Sirolimus results in decreased susceptibility to IL2 protein
CTD PMID:1614535 PMID:10373522 PMID:11355896 PMID:15588918 PMID:15778701 PMID:24971338 PMID:25045214 PMID:29594315 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
JBrowse link
G IL2RA interleukin 2 receptor subunit alpha multiple interactions EXP Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] CTD PMID:8586487 NCBI chr10:6,010,689...6,062,367
Ensembl chr10:6,010,689...6,062,370
JBrowse link
G IL2RG interleukin 2 receptor subunit gamma multiple interactions ISO [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein CTD PMID:12531798 NCBI chr  X:71,107,404...71,111,577
Ensembl chr  X:71,107,404...71,112,108
JBrowse link
G IL3 interleukin 3 multiple interactions ISO Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]] CTD PMID:1376361 NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204
JBrowse link
G IL4 interleukin 4 multiple interactions
decreases expression
ISO [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]]
Sirolimus analog results in decreased expression of IL4 protein; Sirolimus results in decreased expression of IL4 protein
CTD PMID:12406821 PMID:12531798 PMID:15588918 NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
JBrowse link
G IL4R interleukin 4 receptor multiple interactions ISO [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein CTD PMID:12531798 NCBI chr16:27,313,668...27,364,778
Ensembl chr16:27,313,668...27,364,778
JBrowse link
G IL5 interleukin 5 decreases expression ISO Sirolimus analog results in decreased expression of IL5 protein CTD PMID:12406821 NCBI chr 5:132,539,194...132,556,864
Ensembl chr 5:132,541,445...132,556,838
JBrowse link
G IL6 interleukin 6 multiple interactions
increases expression
decreases expression
EXP
ISO
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein
Sirolimus results in increased expression of IL6
Sirolimus results in decreased expression of IL6 mRNA
CTD PMID:15070696 PMID:16314788 PMID:20844194 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G ING4 inhibitor of growth family member 4 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] CTD PMID:21245298 NCBI chr12:6,650,301...6,663,143
Ensembl chr12:6,650,301...6,663,142
JBrowse link
G INS insulin multiple interactions EXP Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] CTD PMID:20936651 PMID:28790194 PMID:28984034 PMID:32283200 NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,341
Ensembl chr11:2,159,779...2,161,341
JBrowse link
G INSIG1 insulin induced gene 1 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of INSIG1 mRNA CTD PMID:25307878 NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
JBrowse link
G IRS1 insulin receptor substrate 1 affects phosphorylation
decreases phosphorylation
decreases degradation
multiple interactions
EXP Sirolimus affects the phosphorylation of IRS1 protein
Sirolimus results in decreased phosphorylation of IRS1 protein
Sirolimus results in decreased degradation of IRS1 protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein]
CTD PMID:16227402 PMID:17908691 PMID:20936651 PMID:28984034 NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,317...226,799,759
JBrowse link
G ITGAM integrin subunit alpha M multiple interactions
increases expression
EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein]; [Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein; Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein]
Sirolimus results in increased expression of ITGAM protein
CTD PMID:20574048 PMID:25758096 NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
JBrowse link
G ITGAV integrin subunit alpha V decreases expression ISO Sirolimus results in decreased expression of ITGAV mRNA; Sirolimus results in decreased expression of ITGAV protein CTD PMID:19922502 NCBI chr 2:186,590,056...186,680,901
Ensembl chr 2:186,590,056...186,680,901
JBrowse link
G JAG1 jagged canonical Notch ligand 1 decreases expression EXP
ISO
Sirolimus results in decreased expression of JAG1 protein CTD PMID:20038814 NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999
JBrowse link
G JMY junction mediating and regulatory protein, p53 cofactor multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] CTD PMID:21245298 NCBI chr 5:79,236,131...79,327,215
Ensembl chr 5:79,236,131...79,327,211
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of JUN protein] CTD PMID:26369790 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G KIFAP3 kinesin associated protein 3 increases expression ISO Sirolimus results in increased expression of KIFAP3 mRNA CTD PMID:21865292 NCBI chr 1:169,921,326...170,085,203
Ensembl chr 1:169,921,326...170,085,208
JBrowse link
G KIFC1 kinesin family member C1 decreases expression ISO Sirolimus results in decreased expression of KIFC1 mRNA CTD PMID:21865292 NCBI chr 6:33,391,524...33,410,226
Ensembl chr 6:33,391,823...33,409,896
JBrowse link
G KIT KIT proto-oncogene, receptor tyrosine kinase multiple interactions EXP KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16597595 NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,918...54,740,715
JBrowse link
G KITLG KIT ligand multiple interactions ISO Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] CTD PMID:10849422 NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851
JBrowse link
G KLF2 Kruppel like factor 2 increases expression EXP Sirolimus results in increased expression of KLF2 mRNA CTD PMID:24356939 NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,817...16,327,874
Ensembl chr19:16,324,817...16,327,874
JBrowse link
G KLF5 Kruppel like factor 5 increases expression ISO Sirolimus results in increased expression of KLF5 mRNA CTD PMID:21865292 NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
JBrowse link
G KLF6 Kruppel like factor 6 decreases phosphorylation ISO Sirolimus results in decreased phosphorylation of KLF6 protein CTD PMID:16611854 NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
JBrowse link
G KLHL24 kelch like family member 24 increases expression
multiple interactions
EXP Sirolimus results in increased expression of KLHL24 mRNA
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of KLHL24 mRNA
CTD PMID:24356939 PMID:25307878 NCBI chr 3:183,635,619...183,684,519
Ensembl chr 3:183,635,610...183,684,519
JBrowse link
G KLK2 kallikrein related peptidase 2 multiple interactions EXP Sirolimus promotes the reaction [Testosterone results in increased expression of KLK2 protein] CTD PMID:21036700 NCBI chr19:50,873,439...50,880,567
Ensembl chr19:50,861,568...50,880,567
JBrowse link
G KLK3 kallikrein related peptidase 3 multiple interactions
increases expression
EXP bicalutamide inhibits the reaction [Sirolimus results in increased expression of KLK3 protein] CTD PMID:18776922 NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764
JBrowse link
G L1CAM L1 cell adhesion molecule affects response to substance EXP L1CAM affects the susceptibility to Sirolimus CTD PMID:21097529 NCBI chr  X:153,861,514...153,886,173
Ensembl chr  X:153,861,514...153,886,173
JBrowse link
G LAMC2 laminin subunit gamma 2 increases expression ISO Sirolimus results in increased expression of LAMC2 mRNA CTD PMID:21865292 NCBI chr 1:183,186,264...183,245,127
Ensembl chr 1:183,186,238...183,245,127
JBrowse link
G LARP1 La ribonucleoprotein 1, translational regulator multiple interactions
increases response to substance
EXP LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]
LARP1 protein results in increased susceptibility to Sirolimus
CTD PMID:25940091 NCBI chr 5:154,682,979...154,817,605
Ensembl chr 5:154,712,843...154,817,605
JBrowse link
G LCN2 lipocalin 2 increases expression ISO Sirolimus results in increased expression of LCN2 mRNA CTD PMID:21865292 NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
JBrowse link
G LIPE lipase E, hormone sensitive type multiple interactions ISO Sirolimus promotes the reaction [Isoproterenol results in increased phosphorylation of LIPE protein] CTD PMID:21042876 NCBI chr19:42,401,512...42,427,421
Ensembl chr19:42,401,514...42,427,388
JBrowse link
G MAD2L1 mitotic arrest deficient 2 like 1 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA CTD PMID:19016759 NCBI chr 4:120,055,623...120,066,848
Ensembl chr 4:120,055,623...120,066,858
JBrowse link
G MAF1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions EXP [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; Sirolimus results in increased expression of and results in decreased phosphorylation of MAF1 protein CTD PMID:31645432 NCBI chr 8:144,104,461...144,107,611
Ensembl chr 8:144,104,461...144,107,611
JBrowse link
G MAP1LC3A microtubule associated protein 1 light chain 3 alpha multiple interactions EXP [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form CTD PMID:21742779 NCBI chr20:34,546,823...34,560,345
Ensembl chr20:34,546,854...34,560,345
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression
increases lipidation
multiple interactions
affects metabolic processing
affects localization
EXP
ISO
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein; Sirolimus results in increased expression of MAP1LC3B protein modified form
Sirolimus results in increased lipidation of MAP1LC3B protein
Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]
CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein]
Sirolimus affects the metabolism of MAP1LC3B protein
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; saikosaponin D inhibits the reaction [Sirolimus results in increased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [saikosaponin D results in decreased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Sirolimus results in increased expression of and results in increased cleavage of MAP1LC3B protein
Sirolimus affects the localization of MAP1LC3B protein
CTD PMID:18640276 PMID:19815708 PMID:21212465 PMID:21681844 PMID:23680031 PMID:24445604 PMID:25884947 PMID:27107786 PMID:29128638 PMID:29518472 PMID:29793971 PMID:30338810 PMID:30555576 PMID:30611790 PMID:31676321 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2 microtubule associated protein 2 increases expression
multiple interactions
ISO Sirolimus results in increased expression of MAP2 protein
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]
CTD PMID:26676567 NCBI chr 2:209,424,047...209,734,118
Ensembl chr 2:209,424,058...209,734,118
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein
Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]
CTD PMID:12411397 PMID:15767555 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein CTD PMID:15767555 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; arsenic trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]
Sirolimus affects the phosphorylation of MAPK1 protein
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]
Sirolimus results in decreased phosphorylation of MAPK1 protein
CTD PMID:15767555 PMID:16255777 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25597859 PMID:25758096 PMID:30905858 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
EXP
ISO
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]
Sirolimus affects the phosphorylation of MAPK3 protein
Sirolimus results in decreased phosphorylation of MAPK3 protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]
CTD PMID:15767555 PMID:16255777 PMID:16391472 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25758096 PMID:30905858 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions EXP [7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] CTD PMID:15767555 NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
JBrowse link
G MBNL2 muscleblind like splicing regulator 2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] CTD PMID:21245298 NCBI chr13:97,141,834...97,394,120
Ensembl chr13:97,221,434...97,394,120
JBrowse link
G MBP myelin basic protein increases expression ISO Sirolimus results in increased expression of MBP protein CTD PMID:20739560 NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member multiple interactions EXP [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased expression of MCL1 protein CTD PMID:15767555 PMID:25758096 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,574,551...150,579,738
Ensembl chr 1:150,574,551...150,579,738
JBrowse link
G MCM2 minichromosome maintenance complex component 2 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA] CTD PMID:11355896 NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,410...127,622,436
JBrowse link
G MCM7 minichromosome maintenance complex component 7 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA] CTD PMID:11355896 NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,728...100,101,940
JBrowse link
G MDM2 MDM2 proto-oncogene multiple interactions
decreases expression
EXP EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] CTD PMID:15625077 PMID:19560264 PMID:21245298 NCBI chr12:68,808,149...68,850,686
Ensembl chr12:68,808,177...68,850,686
JBrowse link
G MIR122 microRNA 122 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA] CTD PMID:23920219 NCBI chr18:58,451,074...58,451,158
Ensembl chr18:58,451,074...58,451,158
JBrowse link
G MIR132 microRNA 132 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA] CTD PMID:23920219 NCBI chr17:2,049,908...2,050,008
Ensembl chr17:2,049,908...2,050,008
JBrowse link
G MIR146A microRNA 146a multiple interactions EXP Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA] CTD PMID:30619488 NCBI chr 5:160,485,352...160,485,450
Ensembl chr 5:160,485,352...160,485,450
JBrowse link
G MIR151A microRNA 151a multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] CTD PMID:21245298 NCBI chr 8:140,732,564...140,732,653
Ensembl chr 8:140,732,564...140,732,653
JBrowse link
G MIR181A2 microRNA 181a-2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] CTD PMID:21245298 NCBI chr 9:124,692,442...124,692,551
Ensembl chr 9:124,692,442...124,692,551
JBrowse link
G MIR190A microRNA 190a multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] CTD PMID:21245298 NCBI chr15:62,823,957...62,824,041
Ensembl chr15:62,823,957...62,824,041
JBrowse link
G MIR212 microRNA 212 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA] CTD PMID:23920219 NCBI chr17:2,050,271...2,050,380
Ensembl chr17:2,050,271...2,050,380
JBrowse link
G MIR29C microRNA 29c multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA] CTD PMID:21245298 NCBI chr 1:207,801,852...207,801,939
Ensembl chr 1:207,801,852...207,801,939
JBrowse link
G MIR324 microRNA 324 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] CTD PMID:21245298 NCBI chr17:7,223,297...7,223,379
Ensembl chr17:7,223,297...7,223,379
JBrowse link
G MIR330 microRNA 330 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MIR330 mRNA CTD PMID:25307878 NCBI chr19:45,638,994...45,639,087
Ensembl chr19:45,638,994...45,639,087
JBrowse link
G MIR379 microRNA 379 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA] CTD PMID:21245298 NCBI chr14:101,022,066...101,022,132
Ensembl chr14:101,022,066...101,022,132
JBrowse link
G MIR433 microRNA 433 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] CTD PMID:21245298 NCBI chr14:100,881,886...100,881,978
Ensembl chr14:100,881,886...100,881,978
JBrowse link
G MIR503 microRNA 503 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] CTD PMID:21245298 NCBI chr  X:134,546,328...134,546,398
Ensembl chr  X:134,546,328...134,546,398
JBrowse link
G MIR508 microRNA 508 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA] CTD PMID:21245298 NCBI chr  X:147,236,913...147,237,027
Ensembl chr  X:147,236,913...147,237,027
JBrowse link
G MIR650 microRNA 650 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA] CTD PMID:21245298 NCBI chr22:22,822,776...22,822,871
Ensembl chr22:22,822,776...22,822,871
JBrowse link
G MIR654 microRNA 654 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA] CTD PMID:21245298 NCBI chr14:101,040,219...101,040,299
Ensembl chr14:101,040,219...101,040,299
JBrowse link
G MIR758 microRNA 758 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA] CTD PMID:21245298 NCBI chr14:101,026,020...101,026,107
Ensembl chr14:101,026,020...101,026,107
JBrowse link
G MIR760 microRNA 760 multiple interactions EXP TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] CTD PMID:21245298 NCBI chr 1:93,846,832...93,846,911
Ensembl chr 1:93,846,832...93,846,911
JBrowse link
G MKI67 marker of proliferation Ki-67 decreases expression
affects expression
multiple interactions
EXP
ISO
Sirolimus results in decreased expression of MKI67 protein
Sirolimus affects the expression of MKI67 mRNA
[ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
CTD PMID:19773376 PMID:24971338 NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
JBrowse link
G MLST8 MTOR associated protein, LST8 homolog multiple interactions EXP Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] CTD PMID:19505958 NCBI chr16:2,204,628...2,209,453
Ensembl chr16:2,204,248...2,209,453
JBrowse link
G MMP1 matrix metallopeptidase 1 increases secretion
increases expression
EXP Sirolimus results in increased secretion of MMP1 protein
Sirolimus results in increased expression of MMP1 mRNA
CTD PMID:21742783 NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,919...102,798,160
JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions ISO Sirolimus inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] CTD PMID:17050028 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
JBrowse link
G MMP9 matrix metallopeptidase 9 decreases expression ISO Sirolimus results in decreased expression of MMP9 mRNA CTD PMID:21865292 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
JBrowse link
G MPZ myelin protein zero increases expression ISO Sirolimus results in increased expression of MPZ protein CTD PMID:20739560 NCBI chr 1:161,303,594...161,309,969
Ensembl chr 1:161,304,735...161,309,968
Ensembl chr 1:161,304,735...161,309,968
JBrowse link
G MSR1 macrophage scavenger receptor 1 decreases expression EXP Sirolimus results in decreased expression of MSR1 mRNA CTD PMID:17016853 NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490
JBrowse link
G MT1E metallothionein 1E multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1E mRNA CTD PMID:25307878 NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112
JBrowse link
G MT1G metallothionein 1G multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1G mRNA CTD PMID:25307878 NCBI chr16:56,666,730...56,668,065
Ensembl chr16:56,666,731...56,668,065
Ensembl chr16:56,666,731...56,668,065
JBrowse link
G MT1H metallothionein 1H multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1H mRNA CTD PMID:25307878 NCBI chr16:56,669,814...56,671,129
Ensembl chr16:56,669,814...56,671,129
JBrowse link
G MT1M metallothionein 1M multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1M mRNA CTD PMID:25307878 NCBI chr16:56,632,659...56,633,981
Ensembl chr16:56,632,659...56,633,981
JBrowse link
G MTOR mechanistic target of rapamycin kinase multiple interactions
increases expression
decreases expression
decreases phosphorylation
increases phosphorylation
decreases activity
increases activity
EXP
ISO
[Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein; [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein; [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to Fulvestrant; [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species; MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA]; Sirolimus inhibits the reaction [Palmitic Acid results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of MTOR protein; sodium arsenite promotes the reaction [Sirolimus results in decreased expression of MTOR protein]
Sirolimus results in increased expression of MTOR protein modified form
Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]
Sirolimus results in increased expression of MTOR mRNA
Sirolimus results in increased phosphorylation of MTOR protein
Sirolimus results in increased activity of MTOR protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol affects the susceptibility to Lipopolysaccharides]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased susceptibility to Resveratrol; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]
Sirolimus results in decreased expression of MTOR mRNA; Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of MTOR protein
CTD PMID:11602639 PMID:12087098 PMID:14673156 PMID:15050414 PMID:15782132 PMID:15919668 PMID:17623046 PMID:17908691 PMID:17968710 PMID:17996122 PMID:18058806 PMID:18381446 PMID:18640276 PMID:18776922 PMID:19016759 PMID:19125612 PMID:19151764 PMID:19505958 PMID:19567381 PMID:19698219 PMID:19815708 PMID:20169165 PMID:20368307 PMID:20680277 PMID:20682991 PMID:21168265 PMID:21187475 PMID:21321189 PMID:21450334 PMID:21742779 PMID:21898527 PMID:22069489 PMID:22363816 PMID:22561310 PMID:22574221 PMID:23111315 PMID:23363784 PMID:23958494 PMID:24971338 PMID:25045214 PMID:25576684 PMID:25884947 PMID:25940091 PMID:26201060 PMID:26282490 PMID:26648565 PMID:27107786 PMID:27133527 PMID:27324791 PMID:27796870 PMID:28342888 PMID:28888487 PMID:29518472 PMID:30132043 PMID:30236763 PMID:30555576 PMID:31051157 PMID:31499194 PMID:32044396 PMID:32329240 NCBI chr 1:11,106,535...11,273,497
Ensembl chr 1:11,106,535...11,262,551
JBrowse link
G MTURN maturin, neural progenitor differentiation regulator homolog multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] CTD PMID:21245298 NCBI chr 7:30,134,986...30,162,764
Ensembl chr 7:30,134,986...30,162,762
JBrowse link
G MYBL2 MYB proto-oncogene like 2 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein CTD PMID:12417722 NCBI chr20:43,667,114...43,716,482
Ensembl chr20:43,667,019...43,716,495
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of MYC protein; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of MYC mRNA; [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein CTD PMID:20054642 PMID:25307878 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G MYF5 myogenic factor 5 decreases expression ISO Sirolimus results in decreased expression of MYF5 protein CTD PMID:30905858 NCBI chr12:80,716,912...80,719,671
Ensembl chr12:80,716,912...80,719,671
JBrowse link
G MYH11 myosin heavy chain 11 multiple interactions
increases expression
EXP [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein
Sirolimus results in increased expression of MYH11 protein
CTD PMID:17908691 NCBI chr16:15,703,135...15,857,032
Ensembl chr16:15,703,135...15,857,028
JBrowse link
G MYH7 myosin heavy chain 7 multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]] CTD PMID:25045214 NCBI chr14:23,412,740...23,435,677
Ensembl chr14:23,412,740...23,435,660
JBrowse link
G MYLK myosin light chain kinase multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] CTD PMID:21245298 NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
JBrowse link
G MYOD1 myogenic differentiation 1 affects expression ISO Sirolimus affects the expression of MYOD1 protein CTD PMID:30905858 NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136
JBrowse link
G MYOF myoferlin multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] CTD PMID:21245298 NCBI chr10:93,306,429...93,482,505
Ensembl chr10:93,306,429...93,482,334
JBrowse link
G NAIP NLR family apoptosis inhibitory protein decreases expression ISO Sirolimus results in decreased expression of NAIP mRNA CTD PMID:9836529 NCBI chr 5:70,968,166...71,025,339
Ensembl chr 5:70,968,483...71,025,114
Ensembl chr 5:70,968,483...71,025,114
JBrowse link
G NANOG Nanog homeobox increases expression ISO Sirolimus results in increased expression of NANOG mRNA CTD PMID:21681844 NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
JBrowse link
G NCF1 neutrophil cytosolic factor 1 multiple interactions
decreases expression
ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein]
Sirolimus results in decreased expression of NCF1 protein
CTD PMID:21195169 NCBI chr 7:74,773,962...74,789,376
Ensembl chr 7:74,773,962...74,789,376
JBrowse link
G NCF2 neutrophil cytosolic factor 2 decreases expression
multiple interactions
ISO Sirolimus results in decreased expression of NCF2 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein]
CTD PMID:21195169 NCBI chr 1:183,555,562...183,590,914
Ensembl chr 1:183,555,563...183,590,876
Ensembl chr 1:183,555,563...183,590,876
JBrowse link
G NCF4 neutrophil cytosolic factor 4 multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] CTD PMID:21195169 NCBI chr22:36,861,006...36,878,015
Ensembl chr22:36,860,988...36,878,017
JBrowse link
G NDC80 NDC80 kinetochore complex component multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA CTD PMID:19016759 NCBI chr18:2,571,557...2,616,635
Ensembl chr18:2,571,557...2,616,635
JBrowse link
G NEK2 NIMA related kinase 2 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA CTD PMID:19016759 NCBI chr 1:211,658,256...211,675,625
Ensembl chr 1:211,658,657...211,675,630
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions
increases activity
ISO NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein]
Sirolimus results in increased activity of NFE2L2 protein
CTD PMID:28624451 PMID:30203046 NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 multiple interactions EXP Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] CTD PMID:15571967 NCBI chr 4:102,501,266...102,617,302
Ensembl chr 4:102,501,331...102,617,302
JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
Sirolimus inhibits the reaction [Isoproterenol results in increased degradation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
CTD PMID:15571967 PMID:18789402 PMID:22363816 PMID:23211629 PMID:25045214 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749
Ensembl chr14:35,401,511...35,404,749
JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions
decreases expression
EXP Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]
Sirolimus results in decreased expression of NLRP3 protein
CTD PMID:30205151 PMID:32645460 NCBI chr 1:247,416,163...247,448,823
Ensembl chr 1:247,416,156...247,449,108
JBrowse link
G NME1 NME/NM23 nucleoside diphosphate kinase 1 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA CTD PMID:19016759 NCBI chr17:51,153,559...51,162,168
Ensembl chr17:51,153,559...51,162,428
Ensembl chr17:51,153,559...51,162,428
JBrowse link
G NMU neuromedin U multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] CTD PMID:21245298 NCBI chr 4:55,595,231...55,636,793
Ensembl chr 4:55,595,229...55,636,698
JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]
CTD PMID:22363816 PMID:23211629 PMID:31499194 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions
increases phosphorylation
decreases expression
EXP
ISO
Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]
Sirolimus results in increased phosphorylation of NOS3 protein
Sirolimus results in decreased expression of NOS3 mRNA; Sirolimus results in decreased expression of NOS3 protein
CTD PMID:17261647 PMID:19520256 PMID:19815708 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
JBrowse link
G NOTCH1 notch receptor 1 affects expression ISO Sirolimus affects the expression of NOTCH1 protein CTD PMID:26676567 NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048
JBrowse link
G NPHS2 NPHS2 stomatin family member, podocin affects expression ISO Sirolimus affects the expression of NPHS2 protein CTD PMID:19671594 NCBI chr 1:179,550,539...179,575,987
Ensembl chr 1:179,550,539...179,575,952
JBrowse link
G NPPA natriuretic peptide A multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]; Sirolimus inhibits the reaction [rosiglitazone results in increased expression of NPPA mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]] CTD PMID:19397913 PMID:25045214 NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
JBrowse link
G NPPB natriuretic peptide B multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]] CTD PMID:25045214 NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
JBrowse link
G NR1H3 nuclear receptor subfamily 1 group H member 3 affects expression EXP Sirolimus affects the expression of NR1H3 protein CTD PMID:17016853 NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] CTD PMID:21245298 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR3C1 nuclear receptor subfamily 3 group C member 1 increases activity ISO Sirolimus results in increased activity of NR3C1 protein CTD PMID:15697228 NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
JBrowse link
G NR5A1 nuclear receptor subfamily 5 group A member 1 multiple interactions EXP Sirolimus inhibits the reaction [Ethanol results in decreased expression of NR5A1 protein] CTD PMID:29524503 NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420
JBrowse link
G NXT1 nuclear transport factor 2 like export factor 1 decreases expression ISO Sirolimus results in decreased expression of NXT1 mRNA CTD PMID:11355896 NCBI chr20:23,350,791...23,354,771
Ensembl chr20:23,350,791...23,354,771
JBrowse link
G OGN osteoglycin increases expression ISO Sirolimus results in increased expression of OGN mRNA CTD PMID:21865292 NCBI chr 9:92,383,268...92,404,699
Ensembl chr 9:92,383,268...92,404,696
JBrowse link
G OLR1 oxidized low density lipoprotein receptor 1 affects expression EXP Sirolimus affects the expression of OLR1 protein CTD PMID:17016853 NCBI chr12:10,158,301...10,172,132
Ensembl chr12:10,158,301...10,172,138
JBrowse link
G OPTN optineurin multiple interactions ISO Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] CTD PMID:25884947 NCBI chr10:13,100,082...13,138,308
Ensembl chr10:13,099,449...13,138,308
JBrowse link
G OXA1L OXA1L mitochondrial inner membrane protein multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] CTD PMID:21245298 NCBI chr14:22,766,688...22,773,042
Ensembl chr14:22,766,522...22,773,042
JBrowse link
G PABPC1 poly(A) binding protein cytoplasmic 1 multiple interactions
decreases expression
EXP Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]
Sirolimus results in decreased expression of PABPC1 protein
CTD PMID:25940091 NCBI chr 8:100,702,916...100,722,088
Ensembl chr 8:100,685,816...100,722,809
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
EXP
ISO
ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]
Sirolimus promotes the reaction [Cadmium results in increased cleavage of PARP1 protein]
[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein]
Sirolimus results in increased expression of PARP1 protein modified form
Sirolimus results in increased cleavage of PARP1 protein
CTD PMID:19682553 PMID:21410490 PMID:24304514 PMID:25307878 PMID:26825372 PMID:29111403 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PAX8 paired box 8 multiple interactions EXP Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] CTD PMID:21245298 NCBI chr 2:113,215,997...113,278,921
Ensembl chr 2:113,215,997...113,278,921
JBrowse link
G PCK1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [troglitazone co-treated with Sirolimus] results in decreased expression of PCK1 mRNA CTD PMID:10446394 NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions
decreases expression
EXP
ISO
[fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA
Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]
Sirolimus results in decreased expression of PCNA protein
CTD PMID:9151781 PMID:11355896 PMID:19016759 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
JBrowse link
G PDCD4 programmed cell death 4 multiple interactions
increases stability
increases expression
EXP
ISO
[resveratrol co-treated with Sirolimus] results in increased stability of PDCD4 protein; Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein]
Sirolimus results in increased stability of PDCD4 protein
resveratrol inhibits the reaction [Sirolimus results in increased stability of PDCD4 protein]
[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein; PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 mRNA]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein]
Sirolimus results in increased expression of PDCD4 protein
Sirolimus results in increased expression of PDCD4 mRNA; Sirolimus results in increased expression of PDCD4 protein
CTD PMID:17259349 PMID:24304514 PMID:24356939 PMID:26369790 NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006
JBrowse link
G PDGFB platelet derived growth factor subunit B multiple interactions EXP [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] CTD PMID:15919668 NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
JBrowse link
G PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha decreases response to substance
increases activity
multiple interactions
EXP Sirolimus results in decreased susceptibility to PIK3CA protein
Sirolimus results in increased activity of PIK3CA protein
Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA]; Wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein]
CTD PMID:10373522 PMID:16227402 PMID:27542212 NCBI chr 3:179,148,114...179,240,093
Ensembl chr 3:179,148,114...179,240,093
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] CTD PMID:17908691 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G PIM1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of PIM1 mRNA CTD PMID:25307878 NCBI chr 6:37,170,152...37,175,428
Ensembl chr 6:37,170,152...37,175,428
JBrowse link
G PKM pyruvate kinase M1/2 multiple interactions EXP [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein CTD PMID:22574221 NCBI chr15:72,199,029...72,231,389
Ensembl chr15:72,199,029...72,231,822
JBrowse link
G PKP4 plakophilin 4 increases expression ISO Sirolimus results in increased expression of PKP4 mRNA CTD PMID:21865292 NCBI chr 2:158,456,952...158,681,429
Ensembl chr 2:158,456,952...158,682,879
Ensembl chr 2:158,456,952...158,682,879
JBrowse link
G PLCL1 phospholipase C like 1 (inactive) increases expression EXP Sirolimus results in increased expression of PLCL1 mRNA CTD PMID:24356939 NCBI chr 2:197,804,593...198,149,873
Ensembl chr 2:197,804,593...198,572,581
JBrowse link
G PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions EXP [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein CTD PMID:20686837 NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,948...59,904,306
Ensembl chr18:59,899,948...59,904,306
JBrowse link
G PML PML nuclear body scaffold increases expression
increases localization
decreases response to substance
EXP Sirolimus results in increased expression of PML protein
Sirolimus results in increased localization of PML protein
PML protein results in decreased susceptibility to Sirolimus
CTD PMID:23440206 NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827
JBrowse link
G PMP22 peripheral myelin protein 22 increases metabolic processing ISO Sirolimus results in increased metabolism of PMP22 protein mutant form CTD PMID:20739560 NCBI chr17:15,229,779...15,265,326
Ensembl chr17:15,229,773...15,272,292
Ensembl chr17:15,229,773...15,272,292
JBrowse link
G PNPLA2 patatin like phospholipase domain containing 2 increases expression ISO Sirolimus results in increased expression of PNPLA2 mRNA; Sirolimus results in increased expression of PNPLA2 protein CTD PMID:20068142 NCBI chr11:818,890...825,573
Ensembl chr11:818,914...825,573
JBrowse link
G PNRC1 proline rich nuclear receptor coactivator 1 increases expression EXP Sirolimus results in increased expression of PNRC1 mRNA CTD PMID:24356939 NCBI chr 6:89,080,749...89,085,160
Ensembl chr 6:89,080,751...89,085,160
JBrowse link
G POLD2 DNA polymerase delta 2, accessory subunit decreases expression ISO Sirolimus results in decreased expression of POLD2 mRNA CTD PMID:11355896 NCBI chr 7:44,114,680...44,123,668
Ensembl chr 7:44,114,681...44,124,358
JBrowse link
G POLR1H RNA polymerase I subunit H multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA] CTD PMID:21245298 NCBI chr 6:30,061,265...30,064,907
Ensembl chr 6:30,058,899...30,064,909
JBrowse link
G POSTN periostin multiple interactions ISO Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 NCBI chr13:37,562,585...37,598,839
Ensembl chr13:37,562,583...37,598,844
JBrowse link
G POU5F1 POU class 5 homeobox 1 increases expression ISO Sirolimus results in increased expression of POU5F1 mRNA; Sirolimus results in increased expression of POU5F1 protein CTD PMID:21681844 NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]] CTD PMID:25045214 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G PPARD peroxisome proliferator activated receptor delta multiple interactions ISO PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] CTD PMID:24898257 NCBI chr 6:35,342,558...35,428,180
Ensembl chr 6:35,342,558...35,428,191
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma affects expression
decreases expression
multiple interactions
EXP
ISO
Sirolimus affects the expression of PPARG protein
Sirolimus results in decreased expression of PPARG mRNA
[Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein
CTD PMID:15358118 PMID:17016853 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
JBrowse link
G PPARGC1A PPARG coactivator 1 alpha multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of PPARGC1A mRNA]
CTD PMID:25045214 PMID:31499194 NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
JBrowse link
G PPL periplakin increases expression ISO Sirolimus results in increased expression of PPL mRNA CTD PMID:21865292 NCBI chr16:4,882,507...4,937,148
Ensembl chr16:4,882,507...4,960,741
JBrowse link
G PPP1R1B protein phosphatase 1 regulatory inhibitor subunit 1B multiple interactions ISO Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] CTD PMID:17209049 NCBI chr17:39,626,735...39,636,625
Ensembl chr17:39,626,740...39,636,626
JBrowse link
G PPP2R1B protein phosphatase 2 scaffold subunit Abeta multiple interactions EXP Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] CTD PMID:27542212 NCBI chr11:111,690,273...111,766,389
Ensembl chr11:111,726,908...111,766,389
JBrowse link
G PRCP prolylcarboxypeptidase increases expression ISO Sirolimus results in increased expression of PRCP mRNA CTD PMID:21865292 NCBI chr11:82,822,936...82,901,691
Ensembl chr11:82,822,936...82,970,584
JBrowse link
G PRF1 perforin 1 decreases expression EXP Sirolimus results in decreased expression of PRF1 protein CTD PMID:16477233 NCBI chr10:70,597,348...70,602,741
Ensembl chr10:70,597,348...70,602,759
JBrowse link
G PRKAA1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein] CTD PMID:21195169 NCBI chr 5:40,759,379...40,798,195
Ensembl chr 5:40,759,379...40,798,374
JBrowse link
G PRKCA protein kinase C alpha multiple interactions EXP Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of PRKCA protein] CTD PMID:23000059 NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
JBrowse link
G PRKCD protein kinase C delta affects localization
multiple interactions
decreases phosphorylation
EXP Sirolimus affects the localization of PRKCD protein
sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein]
CTD PMID:20082316 NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
JBrowse link
G PRKCG protein kinase C gamma increases degradation
multiple interactions
EXP Sirolimus results in increased degradation of PRKCG protein mutant form
Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form]
CTD PMID:20398063 NCBI chr19:53,882,197...53,907,652
Ensembl chr19:53,879,190...53,907,652
JBrowse link
G PRKCH protein kinase C eta decreases response to substance
multiple interactions
EXP PRKCH results in decreased susceptibility to Sirolimus
[Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
CTD PMID:16832347 NCBI chr14:61,187,305...61,550,980
Ensembl chr14:61,187,559...61,550,976
JBrowse link
G PRLR prolactin receptor decreases expression ISO Sirolimus results in decreased expression of PRLR mRNA CTD PMID:21865292 NCBI chr 5:35,048,756...35,230,724
Ensembl chr 5:35,048,756...35,230,487
JBrowse link
G PSMA1 proteasome 20S subunit alpha 1 decreases expression ISO Sirolimus results in decreased expression of PSMA1 mRNA CTD PMID:11355896 NCBI chr11:14,504,876...14,643,662
Ensembl chr11:14,504,874...14,643,635
JBrowse link
G PSMA4 proteasome 20S subunit alpha 4 decreases expression ISO Sirolimus results in decreased expression of PSMA4 mRNA CTD PMID:11355896 NCBI chr15:78,540,405...78,552,417
Ensembl chr15:78,540,405...78,552,417
JBrowse link
G PSMD11 proteasome 26S subunit, non-ATPase 11 decreases expression EXP Sirolimus results in decreased expression of PSMD11 mRNA; Sirolimus results in decreased expression of PSMD11 protein CTD PMID:15782132 NCBI chr17:32,444,510...32,483,319
Ensembl chr17:32,444,379...32,483,319
JBrowse link
G PTEN phosphatase and tensin homolog multiple interactions
decreases expression
decreases response to substance
EXP
ISO
[Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]
Sirolimus inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein]
Sirolimus results in decreased expression of PTEN protein
PTEN protein results in decreased susceptibility to Sirolimus
CTD PMID:18303120 PMID:18622747 PMID:19625624 PMID:21195169 PMID:31676321 NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,863,625...87,971,930
JBrowse link
G PTGER1 prostaglandin E receptor 1 multiple interactions EXP Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] CTD PMID:20335389 NCBI chr19:14,472,466...14,475,354
Ensembl chr19:14,472,466...14,475,354
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions
affects expression
ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]
Sirolimus affects the expression of PTGS2 mRNA
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein]
CTD PMID:22363816 PMID:23211629 PMID:24971338 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G PTK2 protein tyrosine kinase 2 decreases phosphorylation ISO Sirolimus results in decreased phosphorylation of PTK2 protein CTD PMID:19922502 NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
JBrowse link
G PTPN5 protein tyrosine phosphatase non-receptor type 5 multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] CTD PMID:17623046 NCBI chr11:18,727,928...18,792,721
Ensembl chr11:18,727,928...18,792,721
JBrowse link
G PTPRC protein tyrosine phosphatase receptor type C increases expression ISO Sirolimus results in increased expression of PTPRC mRNA CTD PMID:11355896 NCBI chr 1:198,639,025...198,757,476
Ensembl chr 1:198,638,457...198,757,476
JBrowse link
G PTTG1 PTTG1 regulator of sister chromatid separation, securin multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA CTD PMID:19016759 NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739
JBrowse link
G RAC1 Rac family small GTPase 1 decreases expression
multiple interactions
ISO Sirolimus results in decreased expression of RAC1 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein]
CTD PMID:21195169 NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
JBrowse link
G RAD51 RAD51 recombinase multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA CTD PMID:19016759 NCBI chr15:40,694,774...40,732,340
Ensembl chr15:40,694,774...40,732,340
JBrowse link
G RAF1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions EXP [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein CTD PMID:15767555 NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,583,601...12,664,226
Ensembl chr 3:12,583,601...12,664,226
JBrowse link
G RB1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation
EXP
ISO
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with letrozole] results in decreased expression of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]
Sirolimus results in decreased phosphorylation of RB1 protein
[Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein]
CTD PMID:7532117 PMID:8419408 PMID:10373522 PMID:10849422 PMID:12393642 PMID:12417722 PMID:12565877 PMID:14979923 PMID:15753396 PMID:15778701 PMID:17121904 PMID:17700525 PMID:20054642 PMID:21528311 NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
Ensembl chr13:48,303,744...48,599,436
JBrowse link
G RBL1 RB transcriptional corepressor like 1 multiple interactions EXP [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr20:36,996,349...37,096,029
Ensembl chr20:36,996,349...37,095,997
JBrowse link
G RBL2 RB transcriptional corepressor like 2 multiple interactions EXP [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] CTD PMID:10373522 PMID:12417722 NCBI chr16:53,434,471...53,491,648
Ensembl chr16:53,433,977...53,491,648
JBrowse link
G RCAN1 regulator of calcineurin 1 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of RCAN1 mRNA CTD PMID:25307878 NCBI chr21:34,516,442...34,615,123
Ensembl chr21:34,513,142...34,615,113
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
Sirolimus inhibits the reaction [Isoproterenol affects the localization of RELA protein]; Sirolimus inhibits the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
CTD PMID:15571967 PMID:18789402 PMID:22003094 PMID:22363816 PMID:25045214 PMID:31586597 NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
JBrowse link
G REN renin increases expression ISO Sirolimus results in increased expression of REN mRNA CTD PMID:21865292 NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324
JBrowse link
G REST RE1 silencing transcription factor multiple interactions EXP Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] CTD PMID:21245298 NCBI chr 4:56,907,900...56,935,847
Ensembl chr 4:56,907,876...56,966,808
Ensembl chr 4:56,907,876...56,966,808
JBrowse link
G RICTOR RPTOR independent companion of MTOR complex 2 decreases expression EXP Sirolimus results in decreased expression of RICTOR protein CTD PMID:18776922 NCBI chr 5:38,937,920...39,074,421
Ensembl chr 5:38,937,920...39,074,399
JBrowse link
G RPL32 ribosomal protein L32 multiple interactions
decreases expression
EXP LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA] CTD PMID:25940091 NCBI chr 3:12,834,485...12,841,582
Ensembl chr 3:12,834,485...12,841,582
JBrowse link
G RPL7P26 ribosomal protein L7 pseudogene 26 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA] CTD PMID:21245298 NCBI chr 6:17,530,828...17,531,457
Ensembl chr 6:17,530,899...17,531,652
JBrowse link
G RPS20 ribosomal protein S20 multiple interactions
decreases expression
EXP LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA] CTD PMID:25940091 NCBI chr 8:56,067,254...56,074,506
Ensembl chr 8:56,067,295...56,074,581
Ensembl chr 8:56,067,295...56,074,581
JBrowse link
G RPS27L ribosomal protein S27 like multiple interactions EXP Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] CTD PMID:21245298 NCBI chr15:63,148,249...63,157,477
Ensembl chr15:63,125,872...63,158,021
JBrowse link
G RPS6 ribosomal protein S6 multiple interactions
decreases phosphorylation
increases phosphorylation
decreases expression
EXP
ISO
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein
Sirolimus results in increased phosphorylation of RPS6 protein
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
CTD PMID:1614535 PMID:10373522 PMID:12939469 PMID:14502240 PMID:15297429 PMID:15778701 PMID:16832347 PMID:17121904 PMID:17606477 PMID:17908691 PMID:19478560 PMID:19625624 PMID:20038814 PMID:20068142 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21212465 PMID:21245298 PMID:21450334 PMID:22069489 PMID:23363784 PMID:23440206 PMID:24304514 PMID:24375594 PMID:24386346 PMID:24392034 PMID:25940091 PMID:26621329 PMID:27255535 PMID:28342888 PMID:28574600 PMID:28790194 PMID:29793971 PMID:30619488 PMID:30687088 PMID:31051157 PMID:31676321 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
JBrowse link
G RPS6KA1 ribosomal protein S6 kinase A1 increases phosphorylation
multiple interactions
affects localization
EXP
ISO
Sirolimus results in increased phosphorylation of RPS6KA1 protein
Sirolimus results in increased phosphorylation of and results in increased activity of RPS6KA1 protein
Sirolimus affects the localization of RPS6KA1 protein
CTD PMID:19151764 NCBI chr 1:26,529,761...26,575,028
Ensembl chr 1:26,529,761...26,575,030
JBrowse link
G RPS6KA2 ribosomal protein S6 kinase A2 affects localization
increases phosphorylation
ISO Sirolimus affects the localization of RPS6KA2 protein
Sirolimus results in increased phosphorylation of RPS6KA2 protein
CTD PMID:19151764 NCBI chr 6:166,409,364...166,862,525
Ensembl chr 6:166,409,364...166,906,451
JBrowse link
G RPS6KA3 ribosomal protein S6 kinase A3 affects localization
increases phosphorylation
ISO Sirolimus affects the localization of RPS6KA3 protein
Sirolimus results in increased phosphorylation of RPS6KA3 protein
CTD PMID:19151764 NCBI chr  X:20,149,911...20,267,514
Ensembl chr  X:20,149,911...20,267,519
JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 multiple interactions
increases expression
decreases phosphorylation
increases phosphorylation
decreases expression
decreases activity
EXP
ISO
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein]
Sirolimus results in increased expression of RPS6KB1 protein modified form
Sirolimus results in increased phosphorylation of RPS6KB1 protein
Sirolimus results in decreased expression of RPS6KB1 protein modified form
Sirolimus results in decreased phosphorylation of RPS6KB1 protein; Sirolimus results in decreased phosphorylation of S6K protein
[Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein; MRK 003 promotes the reaction [Sirolimus results in decreased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Propranolol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus promotes the reaction [MRK 003 results in decreased activity of RPS6KB1 protein]; Sirolimus promotes the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]
[Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of RPS6KB1 protein
CTD PMID:12411397 PMID:14516795 PMID:14673156 PMID:15070696 PMID:15297429 PMID:15782132 PMID:15914125 PMID:15919668 PMID:16183647 PMID:16391472 PMID:16537399 PMID:16962100 PMID:17616671 PMID:17728140 PMID:17908691 PMID:18021293 PMID:18495876 PMID:18622747 PMID:19246562 PMID:19567381 PMID:19625624 PMID:19810018 PMID:19922502 PMID:20169165 PMID:20574048 PMID:20682991 PMID:20880397 PMID:20936651 PMID:21036700 PMID:21168265 PMID:21321189 PMID:21357504 PMID:21544240 PMID:21858812 PMID:21898527 PMID:21933187 PMID:21984483 PMID:22215663 PMID:22574221 PMID:22863860 PMID:22869613 PMID:23111315 PMID:23255002 PMID:24299490 PMID:24304514 PMID:24375594 PMID:25307878 PMID:25663935 PMID:25758096 PMID:25884947 PMID:25940091 PMID:26282490 PMID:26369790 PMID:26506538 PMID:26621329 PMID:27579538 PMID:27796870 PMID:28984034 PMID:30236763 PMID:30555576 PMID:30661989 PMID:31051157 PMID:31645432 PMID:31676321 PMID:32044396 PMID:32329240 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
JBrowse link
G RPS6KB2 ribosomal protein S6 kinase B2 multiple interactions
decreases activity
EXP MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] CTD PMID:12087098 NCBI chr11:67,428,475...67,435,408
Ensembl chr11:67,428,460...67,435,401
JBrowse link
G RPTOR regulatory associated protein of MTOR complex 1 multiple interactions EXP [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in decreased phosphorylation of RPTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] CTD PMID:18776922 PMID:19505958 PMID:21742779 PMID:22863860 PMID:25940091 NCBI chr17:80,544,838...80,966,368
Ensembl chr17:80,544,819...80,966,371
JBrowse link
G RRAD RRAD, Ras related glycolysis inhibitor and calcium channel regulator multiple interactions EXP Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] CTD PMID:21245298 NCBI chr16:66,921,685...66,925,535
Ensembl chr16:66,921,679...66,925,536
JBrowse link
G RTN4 reticulon 4 multiple interactions ISO Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4 protein] CTD PMID:26648565 NCBI chr 2:54,972,189...55,137,831
Ensembl chr 2:54,972,187...55,112,621
JBrowse link
G RTN4R reticulon 4 receptor multiple interactions ISO Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4R protein] CTD PMID:26648565 NCBI chr22:20,241,415...20,268,318
Ensembl chr22:20,241,415...20,283,246
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions EXP Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
JBrowse link
G S100A4 S100 calcium binding protein A4 decreases expression ISO Sirolimus results in decreased expression of S100A4 mRNA CTD PMID:21865292 NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136
JBrowse link
G S100G S100 calcium binding protein G increases expression ISO Sirolimus results in increased expression of S100G mRNA CTD PMID:21865292 NCBI chr  X:16,649,787...16,654,674
Ensembl chr  X:16,650,158...16,654,670
JBrowse link
G S1PR1 sphingosine-1-phosphate receptor 1 increases expression EXP Sirolimus results in increased expression of S1PR1 mRNA CTD PMID:24356939 NCBI chr 1:101,236,899...101,241,518
Ensembl chr 1:101,236,865...101,243,713
JBrowse link
G SCARB2 scavenger receptor class B member 2 decreases expression EXP Sirolimus results in decreased expression of SCARB2 mRNA CTD PMID:17016853 NCBI chr 4:76,158,737...76,213,824
Ensembl chr 4:76,158,737...76,234,536
JBrowse link
G SCARNA23 small Cajal body-specific RNA 23 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SCARNA23 mRNA CTD PMID:25307878 NCBI chr  X:24,744,441...24,744,570
Ensembl chr  X:24,744,441...24,744,570
JBrowse link
G SCD stearoyl-CoA desaturase multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] CTD PMID:21245298 NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
JBrowse link
G SEMA3A semaphorin 3A multiple interactions ISO
EXP
Sirolimus inhibits the reaction [chromium hexavalent ion results in increased expression of SEMA3A protein] CTD PMID:30236763 NCBI chr 7:83,955,777...84,515,189
Ensembl chr 7:83,955,777...84,492,724
JBrowse link
G SEMA3C semaphorin 3C multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] CTD PMID:21245298 NCBI chr 7:80,742,538...80,922,389
Ensembl chr 7:80,742,538...80,922,359
JBrowse link
G SERPINA1 serpin family A member 1 affects localization EXP Sirolimus affects the localization of SERPINA1 protein CTD PMID:20511674 NCBI chr14:94,376,747...94,390,654
Ensembl chr14:94,376,747...94,390,693
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP
ISO
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]]
CTD PMID:21245298 PMID:31499194 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SESN2 sestrin 2 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SESN2 mRNA CTD PMID:25307878 NCBI chr 1:28,259,452...28,282,491
Ensembl chr 1:28,259,518...28,282,491
JBrowse link
G SHISA2 shisa family member 2 increases expression EXP Sirolimus results in increased expression of SHISA2 mRNA CTD PMID:24356939 NCBI chr13:26,044,597...26,052,016
Ensembl chr13:26,044,597...26,051,031
Ensembl chr13:26,044,597...26,051,031
JBrowse link
G SIRT1 sirtuin 1 multiple interactions
increases response to substance
increases expression
decreases expression
EXP
ISO
[(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of SIRT1 protein; Aspirin inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]
SIRT1 protein results in increased susceptibility to Sirolimus
Sirolimus results in increased expression of SIRT1 protein
Sirolimus inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
CTD PMID:19520256 PMID:22561310 PMID:25307878 NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
JBrowse link
G SIRT2 sirtuin 2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] CTD PMID:21245298 NCBI chr19:38,878,555...38,899,733
Ensembl chr19:38,878,555...38,899,862
JBrowse link
G SKP2 S-phase kinase associated protein 2 decreases expression EXP Sirolimus results in decreased expression of SKP2 protein CTD PMID:21092744 NCBI chr 5:36,152,067...36,184,319
Ensembl chr 5:36,151,989...36,184,319
Ensembl chr 5:36,151,989...36,184,319
JBrowse link
G SLC12A1 solute carrier family 12 member 1 multiple interactions
decreases expression
ISO rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of SLC12A1 protein] CTD PMID:19656910 NCBI chr15:48,206,302...48,304,078
Ensembl chr15:48,178,438...48,304,078
JBrowse link
G SLC12A3 solute carrier family 12 member 3 increases expression ISO Sirolimus results in increased expression of SLC12A3 mRNA CTD PMID:21865292 NCBI chr16:56,865,207...56,915,850
Ensembl chr16:56,865,207...56,915,850
JBrowse link
G SLC15A1 solute carrier family 15 member 1 multiple interactions EXP Sirolimus inhibits the reaction [rosiglitazone results in increased expression of and results in increased activity of SLC15A1 protein] CTD PMID:22108913 NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672
JBrowse link
G SLC16A1 solute carrier family 16 member 1 decreases expression ISO Sirolimus results in decreased expression of SLC16A1 mRNA CTD PMID:21865292 NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,013
JBrowse link
G SLC22A13 solute carrier family 22 member 13 decreases expression ISO Sirolimus results in decreased expression of SLC22A13 mRNA CTD PMID:21865292 NCBI chr 3:38,265,812...38,278,757
Ensembl chr 3:38,265,812...38,278,757
JBrowse link
G SLC5A1 solute carrier family 5 member 1 decreases expression ISO Sirolimus results in decreased expression of SLC5A1 mRNA CTD PMID:21865292 NCBI chr22:32,043,050...32,113,029
Ensembl chr22:32,043,261...32,113,029
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases expression ISO Sirolimus results in increased expression of SLCO1A4 mRNA CTD PMID:11589784 NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
JBrowse link
G SMIM14 small integral membrane protein 14 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] CTD PMID:21245298 NCBI chr 4:39,546,336...39,638,865
Ensembl chr 4:39,546,336...39,638,902
JBrowse link
G SNAI1 snail family transcriptional repressor 1 multiple interactions
increases expression
EXP
ISO
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of SNAI1 mRNA]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of SNAI1 mRNA]
Sirolimus results in increased expression of SNAI1 protein
CTD PMID:28624451 PMID:28888487 PMID:30053495 NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
JBrowse link
G SNCA synuclein alpha multiple interactions EXP Sirolimus inhibits the reaction [Paraquat results in increased expression of SNCA protein] CTD PMID:32306690 NCBI chr 4:89,724,099...89,838,324
Ensembl chr 4:89,700,345...89,838,315
Ensembl chr 4:89,700,345...89,838,315
JBrowse link
G SOD2 superoxide dismutase 2 decreases expression ISO Sirolimus results in decreased expression of SOD2 protein CTD PMID:30905858 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SOX2 SRY-box transcription factor 2 increases expression ISO Sirolimus results in increased expression of SOX2 mRNA CTD PMID:21681844 NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] CTD PMID:31051157 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,650...87,983,426
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions
increases degradation
increases expression
decreases expression
ISO
EXP
bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]
Sirolimus results in increased degradation of SQSTM1 protein
Sirolimus results in increased expression of SQSTM1 protein
[Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased degradation of SQSTM1 protein]
[Sirolimus co-treated with cadmium acetate] results in decreased expression of SQSTM1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [manganese chloride results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]]
CTD PMID:19773376 PMID:24238063 PMID:24304514 PMID:25884947 PMID:28025121 PMID:29128638 PMID:29218509 PMID:29222055 PMID:29505745 PMID:29518472 PMID:29870746 PMID:30338810 PMID:31676321 PMID:32430275 PMID:32645460 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G SRC SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in decreased phosphorylation of SRC protein]; Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein CTD PMID:19151764 PMID:31499194 NCBI chr20:37,344,690...37,406,050
Ensembl chr20:37,344,685...37,406,050
JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 decreases expression ISO Sirolimus results in decreased expression of SREBF1 mRNA CTD PMID:15358118 NCBI chr17:17,811,334...17,837,017
Ensembl chr17:17,810,399...17,837,011
JBrowse link
G SRR serine racemase multiple interactions EXP Sirolimus inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] CTD PMID:24012499 NCBI chr17:2,303,371...2,325,267
Ensembl chr17:2,303,383...2,325,260
JBrowse link
G STARD10 StAR related lipid transfer domain containing 10 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] CTD PMID:21245298 NCBI chr11:72,754,729...72,794,047
Ensembl chr11:72,754,729...72,793,681
JBrowse link
G STAT3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions
EXP
ISO
Sirolimus results in decreased phosphorylation of STAT3 protein
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of STAT3 protein]
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
CTD PMID:16391472 PMID:16427044 PMID:20038814 PMID:26648565 NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
JBrowse link
G STS steroid sulfatase multiple interactions EXP Sirolimus inhibits the reaction [Tretinoin results in increased activity of STS protein] CTD PMID:16178010 NCBI chr  X:7,147,290...7,354,641
Ensembl chr  X:7,147,237...7,804,358
JBrowse link
G SUV39H1 suppressor of variegation 3-9 homolog 1 multiple interactions EXP [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein CTD PMID:31676321 NCBI chr  X:48,695,554...48,709,016
Ensembl chr  X:48,695,554...48,709,012
Ensembl chr  X:48,695,554...48,709,012
JBrowse link
G SYT1 synaptotagmin 1 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] CTD PMID:21245298 NCBI chr12:78,863,982...79,452,008
Ensembl chr12:78,863,993...79,452,008
JBrowse link
G TAF12 TATA-box binding protein associated factor 12 decreases expression ISO Sirolimus results in decreased expression of TAF12 mRNA CTD PMID:11355896 NCBI chr 1:28,602,850...28,648,707
Ensembl chr 1:28,589,323...28,643,085
JBrowse link
G TAL1 TAL bHLH transcription factor 1, erythroid differentiation factor multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] CTD PMID:21245298 NCBI chr 1:47,216,290...47,232,389
Ensembl chr 1:47,216,290...47,232,220
JBrowse link
G TARDBP TAR DNA binding protein multiple interactions ISO Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein] CTD PMID:25884947 NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,662...11,030,528
Ensembl chr 1:11,012,662...11,030,528
Ensembl chr 1:11,012,662...11,030,528
JBrowse link
G TARS1 threonyl-tRNA synthetase 1 decreases expression ISO Sirolimus results in decreased expression of TARS mRNA CTD PMID:11355896 NCBI chr 5:33,440,696...33,468,091
Ensembl chr 5:33,440,696...33,468,091
Ensembl chr 5:33,440,696...33,468,091
JBrowse link
G TAX1BP1 Tax1 binding protein 1 increases expression ISO Sirolimus results in increased expression of TAX1BP1 mRNA CTD PMID:11355896 NCBI chr 7:27,739,373...27,829,767
Ensembl chr 7:27,739,331...27,844,564
JBrowse link
G TCF19 transcription factor 19 multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of TCF19 mRNA CTD PMID:19016759 NCBI chr 6:31,158,589...31,164,215
Ensembl chr 6:31,158,547...31,167,159
JBrowse link
G TEAD1 TEA domain transcription factor 1 multiple interactions EXP Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] CTD PMID:21245298 NCBI chr11:12,674,421...12,944,737
Ensembl chr11:12,674,421...12,944,737
JBrowse link
G TERT telomerase reverse transcriptase decreases expression EXP Sirolimus results in decreased expression of TERT mRNA; Sirolimus results in decreased expression of TERT protein CTD PMID:12939469 PMID:16455087 PMID:17996122 PMID:20863555 NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068
Ensembl chr 5:1,253,147...1,295,068
JBrowse link
G TFEB transcription factor EB affects localization EXP Sirolimus affects the localization of TFEB protein CTD PMID:28366621 NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions
decreases expression
increases response to substance
EXP
ISO
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
Sirolimus results in decreased expression of TGFB1 mRNA
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
TGFB1 protein results in increased susceptibility to Sirolimus
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]
CTD PMID:10535884 PMID:12417722 PMID:14979923 PMID:17050028 PMID:17550925 PMID:17700525 PMID:20844194 PMID:24971338 PMID:28342888 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
JBrowse link
G TGFBR3 transforming growth factor beta receptor 3 increases expression ISO Sirolimus results in increased expression of TGFBR3 mRNA CTD PMID:11355896 NCBI chr 1:91,680,343...91,906,002
Ensembl chr 1:91,680,343...91,906,335
JBrowse link
G TGM2 transglutaminase 2 decreases expression ISO Sirolimus results in decreased expression of TGM2 mRNA CTD PMID:11355896 NCBI chr20:38,127,385...38,166,508
Ensembl chr20:38,127,385...38,166,578
JBrowse link
G TIMELESS timeless circadian regulator multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of TIMELESS mRNA CTD PMID:19016759 NCBI chr12:56,416,363...56,449,426
Ensembl chr12:56,416,363...56,449,426
JBrowse link
G TIMP3 TIMP metallopeptidase inhibitor 3 decreases expression EXP Sirolimus results in decreased expression of TIMP3 mRNA; Sirolimus results in decreased expression of TIMP3 protein CTD PMID:21742783 NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041
JBrowse link
G TMEM14C transmembrane protein 14C multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] CTD PMID:21245298 NCBI chr 6:10,723,070...10,731,127
Ensembl chr 6:10,722,915...10,731,129
JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases expression
decreases secretion
increases expression
EXP
ISO
[Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]
Sirolimus results in decreased expression of TNF mRNA
Sirolimus results in decreased secretion of TNF protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]
Sirolimus results in increased expression of TNF
CTD PMID:12531798 PMID:14502240 PMID:16314788 PMID:19567381 PMID:19810018 PMID:21600178 PMID:22069489 PMID:22363816 PMID:24971338 PMID:25045214 PMID:31332898 PMID:31586597 PMID:31676321 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G TNFSF11 TNF superfamily member 11 multiple interactions ISO Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
JBrowse link
G TP53 tumor protein p53 multiple interactions
increases expression
decreases phosphorylation
EXP
ISO
[Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein]
Sirolimus results in increased expression of TP53 mRNA
Sirolimus results in decreased phosphorylation of TP53 protein
CTD PMID:11602639 PMID:19560264 PMID:24971338 PMID:30555576 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
Ensembl chr17:7,661,779...7,687,538
JBrowse link
G TP63 tumor protein p63 decreases expression EXP
ISO
Sirolimus results in decreased expression of TP63 protein
Sirolimus results in decreased expression of TRP63 protein
CTD PMID:20038814 NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276
JBrowse link
G TP73 tumor protein p73 multiple interactions
increases expression
EXP [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein; Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA]; Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter]; Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter]; Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA]; TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin]
Sirolimus results in increased expression of TP73 protein
CTD PMID:20686837 PMID:21245298 NCBI chr 1:3,652,516...3,736,201
Ensembl chr 1:3,652,516...3,736,201
JBrowse link
G TPP2 tripeptidyl peptidase 2 multiple interactions ISO Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein] CTD PMID:20643100 NCBI chr13:102,596,985...102,679,958
Ensembl chr13:102,596,986...102,679,958
JBrowse link
G TRIB3 tribbles pseudokinase 3 multiple interactions EXP [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of TRIB3 mRNA CTD PMID:25307878 NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559
JBrowse link
G TRPM6 transient receptor potential cation channel subfamily M member 6 multiple interactions
increases expression
ISO rosiglitazone inhibits the reaction [Sirolimus results in increased expression of TRPM6 protein] CTD PMID:19656910 NCBI chr 9:74,722,495...74,887,921
Ensembl chr 9:74,722,495...74,888,094
JBrowse link
G TSC1 TSC complex subunit 1 multiple interactions ISO Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein] CTD PMID:18495876 NCBI chr 9:132,891,349...132,945,269
Ensembl chr 9:132,891,348...132,946,874
JBrowse link
G TSC2 TSC complex subunit 2 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with resveratrol] results in increased cleavage of PARP1 protein]
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus co-treated with resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein]
Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
CTD PMID:19420259 PMID:24304514 PMID:31676321 NCBI chr16:2,047,804...2,089,491
Ensembl chr16:2,047,967...2,089,491
JBrowse link
G TTK TTK protein kinase multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of TTK mRNA CTD PMID:19016759 NCBI chr 6:80,004,147...80,042,651
Ensembl chr 6:80,003,887...80,042,527
JBrowse link
G TYMS thymidylate synthetase decreases expression EXP Sirolimus results in decreased expression of TYMS; Sirolimus results in decreased expression of TYMS mRNA CTD PMID:19764996 PMID:20682991 NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
JBrowse link
G ULK1 unc-51 like autophagy activating kinase 1 multiple interactions ISO
EXP
Sirolimus affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein] CTD PMID:29128638 PMID:29518472 NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
JBrowse link
G URI1 URI1 prefoldin like chaperone decreases response to substance EXP URI1 results in decreased susceptibility to Sirolimus CTD PMID:21397856 NCBI chr19:29,923,650...30,016,612
Ensembl chr19:29,923,644...30,016,612
JBrowse link
G VASN vasorin decreases expression ISO Sirolimus results in decreased expression of VASN mRNA CTD PMID:17028423 NCBI chr16:4,371,848...4,383,538
Ensembl chr16:4,371,848...4,383,538
JBrowse link
G VCAN versican increases expression ISO Sirolimus results in increased expression of VCAN mRNA CTD PMID:21865292 NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303
JBrowse link
G VCP valosin containing protein multiple interactions EXP
ISO
Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]
Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein]
CTD PMID:25884947 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions
decreases expression
EXP
ISO
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
[Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of VEGFA mRNA
Sirolimus results in decreased expression of VEGFA protein
Sirolimus results in decreased expression of VEGFA mRNA
CTD PMID:15050414 PMID:15930297 PMID:16682453 PMID:17968710 PMID:20554536 PMID:24971338 PMID:31332898 NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
JBrowse link
G VIM vimentin multiple interactions EXP
ISO
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of VIM protein]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]
CTD PMID:28624451 PMID:28888487 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
JBrowse link
G WT1 WT1 transcription factor decreases expression EXP Sirolimus results in decreased expression of WT1 mRNA; Sirolimus results in decreased expression of WT1 protein; Sirolimus results in decreased expression of WT1 protein mutant form CTD PMID:15782132 PMID:18927120 NCBI chr11:32,387,775...32,435,539
Ensembl chr11:32,387,775...32,435,564
Ensembl chr11:32,387,775...32,435,564
JBrowse link
G XBP1 X-box binding protein 1 multiple interactions EXP Sirolimus inhibits the reaction [arsenite results in increased splicing of XBP1 mRNA] CTD PMID:22215663 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
JBrowse link
G XIAP X-linked inhibitor of apoptosis multiple interactions EXP Sirolimus promotes the reaction [Cisplatin results in decreased expression of XIAP protein] CTD PMID:18058806 NCBI chr  X:123,859,708...123,913,972
Ensembl chr  X:123,859,724...123,913,976
Ensembl chr  X:123,859,724...123,913,976
JBrowse link
G YPEL1 yippee like 1 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] CTD PMID:21245298 NCBI chr22:21,697,536...21,735,794
Ensembl chr22:21,697,536...21,735,794
JBrowse link
G ZBED8 zinc finger BED-type containing 8 increases expression EXP Sirolimus results in increased expression of ZBED8 mRNA CTD PMID:24356939 NCBI chr 5:160,393,148...160,400,054
Ensembl chr 5:160,393,148...160,400,054
JBrowse link
G ZIC2 Zic family member 2 multiple interactions EXP Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] CTD PMID:21245298 NCBI chr13:99,981,784...99,986,765
Ensembl chr13:99,981,784...99,986,765
JBrowse link
G ZNF628 zinc finger protein 628 decreases expression EXP Sirolimus results in decreased expression of ZNF628 mRNA CTD PMID:24356939 NCBI chr19:55,476,603...55,484,487
Ensembl chr19:55,476,617...55,484,487
JBrowse link
G ZWINT ZW10 interacting kinetochore protein multiple interactions EXP [fulvestrant co-treated with Sirolimus] results in decreased expression of ZWINT mRNA CTD PMID:19016759 NCBI chr10:56,357,227...56,361,273
Ensembl chr10:56,357,227...56,361,273
JBrowse link
everolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 affects stability
affects response to substance
multiple interactions
ISO
EXP
ABCB1A protein affects the stability of Everolimus
ABCB1 polymorphism affects the susceptibility to Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan]
CTD PMID:24727322 PMID:27169792 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 decreases activity EXP Everolimus results in decreased activity of ABCB11 protein CTD PMID:23956101 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) affects stability
multiple interactions
ISO ABCG2 protein affects the stability of Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan]
CTD PMID:24727322 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G AKT1 AKT serine/threonine kinase 1 increases phosphorylation
decreases phosphorylation
EXP Everolimus results in increased phosphorylation of AKT1 protein
Everolimus results in decreased phosphorylation of AKT1 protein
CTD PMID:16033851 PMID:22885370 PMID:23300809 PMID:28711525 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 decreases expression
multiple interactions
EXP Everolimus results in decreased expression of BIRC5 protein
Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
CTD PMID:21601561 PMID:28711525 PMID:28947240 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G BRD4 bromodomain containing 4 multiple interactions EXP [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] CTD PMID:25537515 NCBI chr19:15,235,519...15,332,539
Ensembl chr19:15,235,519...15,332,545
JBrowse link
G CASP3 caspase 3 increases cleavage EXP Everolimus results in increased cleavage of CASP3 protein CTD PMID:15940265 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CCNA2 cyclin A2 decreases expression EXP Everolimus results in decreased expression of CCNA2 protein CTD PMID:16856892 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
JBrowse link
G CCND1 cyclin D1 decreases expression
multiple interactions
EXP Everolimus results in decreased expression of CCND1 protein
[letrozole co-treated with Everolimus] results in decreased expression of CCND1 protein
CTD PMID:16033851 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CCND2 cyclin D2 multiple interactions
decreases expression
EXP [letrozole co-treated with Everolimus] results in decreased expression of CCND2 protein
Everolimus results in decreased expression of CCND2 protein
CTD PMID:16033851 NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
Ensembl chr12:4,269,771...4,305,353
JBrowse link
G CCND3 cyclin D3 decreases expression EXP Everolimus results in decreased expression of CCND3 protein CTD PMID:16856892 NCBI chr 6:41,934,933...42,048,894
Ensembl chr 6:41,934,933...42,050,357
Ensembl chr 6:41,934,933...42,050,357
JBrowse link
G CDH1 cadherin 1 increases expression EXP Everolimus results in increased expression of CDH1 protein CTD PMID:28258630 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,541
JBrowse link
G CES1 carboxylesterase 1 decreases activity EXP Everolimus results in decreased activity of CES1 protein CTD PMID:24727322 NCBI chr16:55,802,851...55,833,127
Ensembl chr16:55,802,851...55,833,337
JBrowse link
G CES2 carboxylesterase 2 decreases activity EXP Everolimus results in decreased activity of CES2 protein CTD PMID:24727322 NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
JBrowse link
G EGFR epidermal growth factor receptor multiple interactions
increases expression
EXP platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]
Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein
CTD PMID:28711525 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G EIF4E eukaryotic translation initiation factor 4E increases phosphorylation
multiple interactions
EXP Everolimus results in increased phosphorylation of EIF4E protein
Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein]
CTD PMID:16033851 NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,871,684...98,930,637
JBrowse link
G EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
decreases phosphorylation
EXP [Letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16033851 PMID:16856892 PMID:16951235 PMID:21372221 PMID:28711525 NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
JBrowse link
G EIF4G1 eukaryotic translation initiation factor 4 gamma 1 multiple interactions EXP Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of EIF4G1 protein] CTD PMID:16033851 NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions EXP Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
JBrowse link
G IGF1R insulin like growth factor 1 receptor increases expression
multiple interactions
EXP Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein
platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein]
CTD PMID:28711525 NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
JBrowse link
G ITGAM integrin subunit alpha M multiple interactions EXP Everolimus promotes the reaction [Tretinoin results in increased expression of ITGAM protein] CTD PMID:29743969 NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
JBrowse link
G MMP9 matrix metallopeptidase 9 multiple interactions EXP Everolimus inhibits the reaction [4-cresol results in increased expression of MMP9 protein] CTD PMID:30910523 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
JBrowse link
G MTOR mechanistic target of rapamycin kinase multiple interactions
decreases activity
EXP
ISO
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin]
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]
Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein
CTD PMID:16033851 PMID:20890178 PMID:21622721 PMID:24989011 PMID:30910523 NCBI chr 1:11,106,535...11,273,497
Ensembl chr 1:11,106,535...11,262,551
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases response to substance
increases expression
EXP [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene]
Everolimus results in increased expression of MYC protein
CTD PMID:25537515 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G NGF nerve growth factor multiple interactions ISO Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] CTD PMID:24989011 NCBI chr 1:115,285,915...115,338,253
Ensembl chr 1:115,285,917...115,338,256
Ensembl chr 1:115,285,917...115,338,256
Ensembl chr 1:115,285,917...115,338,256
JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions
decreases expression
EXP Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; Cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein] CTD PMID:19520256 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 decreases activity ISO Everolimus results in decreased activity of NR1I3 protein CTD PMID:30203046 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein CTD PMID:28947240 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression ISO Everolimus results in increased expression of PTGS2 mRNA; Everolimus results in increased expression of PTGS2 protein CTD PMID:15937522 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G PTK2 protein tyrosine kinase 2 decreases expression EXP Everolimus results in decreased expression of PTK2 protein modified form CTD PMID:28258630 NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
JBrowse link
G RB1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation
EXP [letrozole co-treated with Everolimus] results in decreased phosphorylation of and affects the activity of RB1 protein; Everolimus results in decreased phosphorylation of and affects the activity of RB1 protein
Everolimus results in decreased phosphorylation of RB1 protein
CTD PMID:16033851 PMID:16856892 NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
Ensembl chr13:48,303,744...48,599,436
JBrowse link
G RHOA ras homolog family member A decreases expression
multiple interactions
EXP Everolimus results in decreased expression of RHOA protein
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased expression of RHOA protein]
CTD PMID:28258630 PMID:30910523 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,145...49,412,998
Ensembl chr 3:49,359,145...49,412,998
JBrowse link
G RPS6 ribosomal protein S6 multiple interactions
decreases phosphorylation
EXP [Letrozole co-treated with Everolimus] results in decreased phosphorylation of RPS6 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6 protein]
Everolimus results in decreased phosphorylation of RPS6 protein
CTD PMID:16033851 PMID:21372221 PMID:22885370 PMID:23151917 PMID:23300809 PMID:24386346 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 multiple interactions ISO
EXP
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]]
Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6KB1 protein]; Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]
CTD PMID:16033851 PMID:19567381 PMID:24989011 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
JBrowse link
G SIRT1 sirtuin 1 multiple interactions
decreases expression
EXP Aspirin inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein] CTD PMID:19520256 NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
JBrowse link
G SRC SRC proto-oncogene, non-receptor tyrosine kinase decreases expression EXP Everolimus results in decreased expression of SRC protein modified form CTD PMID:28258630 NCBI chr20:37,344,690...37,406,050
Ensembl chr20:37,344,685...37,406,050
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G VIM vimentin decreases expression EXP Everolimus results in decreased expression of VIM protein CTD PMID:28258630 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 24372
    role 24283
      biological role 24250
        immunomodulator 14991
          immunosuppressive agent 12907
            sirolimus 489
              everolimus 38
              ridaforolimus 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 24372
    subatomic particle 24329
      composite particle 24329
        hadron 24329
          baryon 24329
            nucleon 24329
              atomic nucleus 24329
                atom 24329
                  main group element atom 24177
                    p-block element atom 24177
                      carbon group element atom 23954
                        carbon atom 23912
                          organic molecular entity 23912
                            organic group 22192
                              organic divalent group 22166
                                organodiyl group 22166
                                  carbonyl group 22149
                                    carbonyl compound 22149
                                      carboxylic acid 21198
                                        carboacyl group 19357
                                          univalent carboacyl group 19357
                                            carbamoyl group 18754
                                              carboxamide 18754
                                                lactam 8507
                                                  macrolide lactam 794
                                                    sirolimus 489
                                                      everolimus 38
                                                      ridaforolimus 0
paths to the root